CURRICULUM VITAE AND BIBLIOGRAPHY

Part I: General Information

Date Prepared: September 1, 2010

Name: **Laurence A. Turka, M.D**

Place of Birth: New York, NY

Business Address: Beth Israel Deaconess Medical Center
The Transplant Institute
330 Brookline Avenue, E/CLS 607
Boston, MA 02215 USA

Office Address: Beth Israel Deaconess Medical Center
The Transplant Institute
Center for Life Sciences (CLS) Building
3 Blackfan Circle, CLS 607
Boston, MA 02115 USA

E-mail: lturka@bidmc.harvard.edu

Office Telephone: 617-735-2899
Office Fax: 617-735-2902

Administrative Coordinator: Jennifer Mason, 617 735-2919
jkmason@bidmc.harvard.edu

Research Administrator: Minessa Mushtaq, 617-735-2858
mmushtaq@bidmc.harvard.edu

Education:

1974-1978	Colgate University, Hamilton, NY, B.A. (Biochemistry, Summa Cum Laude)
1978-1982	Yale Medical School, New Haven, CT, M.D. (Cum Laude)
1995	University of Pennsylvania, M.A. (Hon)

Post Doctoral Training:

1982-1983	Intern in Medicine, Yale-New Haven Hospital, New Haven, CT
1983-1985	Resident in Medicine, Yale-New Haven Hospital, New Haven, CT
1985-1988	Fellowship, Nephrology, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA

Certifications:

1985	American Board of Internal Medicine
1988	American Board of Internal Medicine, Nephrology

Academic Appointments:

1988 - 1993	Assistant Professor of Medicine, University of Michigan

1993 - 1994	Associate Professor of Medicine (tenure), University of Michigan
1993 - 1994	Director, Immunobiology and Tumor Immunology Program, University of Michigan Cancer Center
1994 - 1998	Associate Professor of Medicine (tenure), Univ. of Pennsylvania
1994 - 1996	Director of Immunology Programs, Institute for Human Gene Therapy, University of Pennsylvania
1995 - 2009	Adjunct Associate Professor, The Wistar Institute
1998 - 2009	Professor of Medicine (tenure), University of Pennsylvania
1998 - 2007	Chief, Renal-Electrolyte and Hypertension Division, Department of Medicine, University of Pennsylvania
1998- 2009	Professor of Surgery, University of Pennsylvania
1999 - 2009	C. Mahlon Kline Professor of Medicine, University of Pennsylvania
2000 - 2009	Professor of Pediatrics, University of Pennsylvania
2003 - 2009	Professor of Pathology and Laboratory Medicine, University of Pennsylvania
2009 -	Adjunct Professor of Medicine, University of Pennsylvania
2009 -	Lecturer on Medicine and Surgery, Harvard University

Hospital Appointments:

1988 - 1994	Staff Physician, University of Michigan Medical Center
1994 - 2004	Staff Physician, Philadelphia VA Medical Center
1994 - 2009	Staff Physician, Hospital of the University of Pennsylvania
2009 -	Co-Research Director, The Transplant Institute, Beth Israel Deaconess Medical Center
2009 -	Co-Chief, Division of Transplant Immunology, Department of Medicine, Beth Israel Deaconess Medical Center

Major Committee Assignments:

Medical School and Medical Center:
University of Pennsylvania

1994-	Flow Cytometry Advisory Committee (Chair, 2005)
1994 - 1996	Institute for Human Gene Therapy Advisory Committee
1994 - 1996	Institute for Human Gene Therapy Immunology and Hematopoiesis Faculty Search Committee
1995 - 1996	Student Affairs Committee, Immunology Graduate Group (responsible for preliminary exams for graduate students)
1996 - 2001	Curriculum Committee, Immunology Graduate Group
1996 -	Advisory Committee, Combined Degree Program
1997 - 1999	Dissertation Awards Committee, Immunology Graduate Group
1997 - 1999	Executive Committee, Immunology Graduate Group
1997 - 1999	Chair, Student Affairs Committee, Immunology Graduate Group
1999	Search Committee, Assoc. Chief of Staff, Philadelphia VA Medical Center
1999 - 2000	Clinical Investigator Pathway Council, Department of Medicine
2000 -	Immunology Graduate Group Admissions Committee
2000	Member, Search Committee for Chairman of Pediatrics and Physician-in-Chief, University of Pennsylvania and Children's Hospital of Philadelphia.
2001 - 2003	Student Affairs Committee, Immunology Graduate Group
2002	Chair, Immunology and Transplantation Theme Group (as part of School of Medicine Strategic Plan)
2002 -	Ad hoc member, School of Medicine Dean's Recruitment Advisory Committee
2003	Member, Department of Medicine Strategic Planning Steering Committee
2003	Member, Department of Medicine Review Oversight Committee

2004 Chair, Search Committee for Chief of Rheumatology Division, Department of Medicine, University of Pennsylvania
2005 - 2006 Member, University of Pennsylvania School of Medicine Committee on Resources for Faculty
2008 - 2009 Chair, Search Committee for Chief of Rheumatology Division, Department of Medicine, University of Pennsylvania

Harvard Medical School
2010 Member, Committee for Immunology, Harvard Medical School
2010 Member, Executive Committee for Immunology, Harvard Medical School

National and Regional:
1991-1994 National Kidney Foundation of Michigan,
1991-1996 American Society of Transplant Physicians Awards Comm., co-chair 1996
1992 Ad hoc reviewer, VA Merit Review, Hematology Study Section,
1993 Ad hoc reviewer, VA Merit Review, Immunology Study Section
1993 Site Visitor, NIH Program Project "Pathophysiology of Renal Allograft Dysfunction", Thomas Coffman, P.I., Duke U.
1993-1996 Ad hoc member, NIH Immunobiology Study Section
1993 Ad hoc reviewer, National Kidney Foundation
1994 Ad hoc reviewer, Kidney Foundation of Canada
1996-1997 Ad hoc member, NIH Surgery, Anesthesia & Trauma Study Section, (reviews transplantation immunology grants)
1998 External advisor for NIAID Autoimmunity Program Project Directors Meeting
1998 Ad hoc reiviewer, United Kingdom Medical Research Council
1998 Expert Panel reviewer of NIAID Research Plan for Immune Tolerance
1998 NIH Special Study Section ZRG1 ALY (3)
1999 NIH Special Study Section ZRG1 SSS-4 (02)
1998-2002 Permanent member, NIH Surgery, Anesthesia & Trauma Study Section
1999 - Scientific Review Committee, NIAID/JDF Immune Tolerance Network
1999 - Steering Committee, NIAID/JDF Immune Tolerance Network
1999 - Medical Sciences Review Committee, Juvenile Diabetes Foundation
2000 Ad hoc reviewer, United Kingdom Medical Research Council
2000 Ad hoc site visit reviewer, JDF-Harvard Center for Islet Transplantation
2000 Chairperson, NIH Non-Human Primate Transplant Tolerance Cooperative Agreement Study Section
2001 NIAID Special Emphasis Panel for RFA AI-01-006, Non-Human Primate Immune Tolerance Cooperative Study Group
2002 - Co-chair, Tolerance Assay Subgroup, NIAID/JDF Immune Tolerance Network
2002 NIH Special Study Section SSS-H (03)
2002 Chair, Study Section/Special Emphasis Panel ZRG1 ALY(01)
2002 Member, NIH Center for Scientific Review Studies Section Boundary Team for Immunology
2002 - Executive Committee, NIAID/JDF Immune Tolerance Network
2002 Ad hoc reviewer, The Wellcome Trust
2002 - 2007 Member, NIAID Board of Scientific Counselors
2003 Chair, Study Section/Special Emphasis Panel ZRG1 EI 04
2003 - 2004 Chair, Immune Tolerance Network Internal Review Committee
2003 - 2008 Scientific Advisory Board, Roche Organ Transplantation Research Foundation
2004 Ad hoc reviewer, Israel Science Foundation
2004 Member, Transplant Center Review Committee, Beth Israel Deaconess Medical Center, Boston MA
2004 - Deputy Director, Immune Tolerance Network

2005 Ad hoc reviewer, National Kidney Research Fund, UK
2005 Ad hoc member, Novartis Scientific Advisory Board
2005 Member, NIH Expert Panel on Transplantation Research
2005 - 2007 Chair, NIAID Board of Scientific Counselors
2006 - Secretary, and Founding Member of Board of Directors, Immune Tolerance Institute
2007 - Member, Guy's-St. Thomas Biomedical Research Centre Scientific Advisory Board
2007 NIAID Advisory Panel – 2007 Stategic Plan Update
2008 Chair, NIH Study Section/Special Emphasis Panel ZRG1 IMM-K (02)
2009 Chair, NIH Study Section/Special Emphasis Panel ZRG1 IMM-J (03)
2010 Ad hoc reviewer, INSERM

Professional Societies:

American Society of Transplantation
1997 - 1998 Chairman, Program Committee
1998 - 2002 Chairman, Education Committee
1998 - 2003 Member, Board of Directors
1998 - 2003 AST/ASTS Joint Executive Council
2000 - 2003 Financial Advisory Commitee
2000 - 2003 President Elect, President, Past-President

American Association of Immunologists
2001 - 2004 Program Committee

American Society of Nephrology
1997 Program Committee
1999 - 2001 Transplant Advisory Group, co-chair 2001
2001 - 2004 Basic Science Committee
2001 Nominating Committee

2007 Society for Innate Immunity and Transplantation (founding member)

American Society for Clinical Investigation
2007 - Council Member and Officer

Editorial Board:

1992 - 1999 Associate Editor; Journal of Immunology
1996 - 2002 Editorial Board; Transplantation
1996 - 2001 Editorial Board; Journal of the American Society of Nephrology
1998 - 2000 Editorial Board; Graft
1998 - 2000 Editorial Board; Transplantation Immunology
1999 - 2003 Section Editor; Journal of Immunology
2001 - 2003 Editorial Board; Current Opinion in Nephrology & Hypertension
2002 - 2003 Editorial Board; Transplantation Proceedings
2002 - 2000 Editorial Board; Immunological Reviews
2003 - 2006 Associate Editor; American Journal of Transplantation
2003 Guest Editor; Immunological Reviews
2003 - 2007 Consulting Editor; Journal of Clinical Investigation

2007 - present Editor-in-Chief Journal of Clinical Investigation

1993 - present Ad hoc reviewer; Kidney International

1994 - present Ad hoc reviewer; Diabetes
1994 - present Ad hoc reviewer; Gastroenterology
1994 - present Ad hoc reviewer; Journal of Clnical Investigation
1995 - present Ad hoc reviewer; Proceedings of the National Academy of Sciences
1995 - present Ad hoc reviewer; International Immunology
1996 - present Ad hoc reviewer; Immunity
1997 - present Ad hoc reviewer; Journal of the American Medical Association
1998 - present Ad hoc reviewer; New England Journal of Medicine
1998 - present Ad hoc reviewer; Nature Medicine
1999 - present Ad hoc reviewer; Journal of Experimental Medicine
1999 - present Ad hoc reviewer; Blood
2001 - present Ad hoc reviewer; Nature Immunology
2002 - present Ad hoc reviewer; Nature Reviews Immunology
2004 - present Ad hoc reviewer; Science
2004 - present Ad hoc reviewer; Nature

Awards and Honors:

1974-1978 Alumni War Memorial Scholar, Colgate University
1976-1978 Charles A. Dana Scholar, Colgate University
1977 Phi Beta Kappa
1977 Sisson Mathematics Prize, Colgate University
1987 Travel Award, American Society for Histocompatibility and Immunogenetics
1988 Young Investigator Award, American Society of Transplant Physicians
1988 Joseph Shankman Award (Massachusetts Chapter of National Kidney Foundation)
1993 Jerome W. Conn Award for Distinguished Research (University of Michigan)
1993 Young Investigator Award, Central Society for Clinical Research
1995 American Society for Clinical Investigation
1996 Young Investigator Award, American Society of Nephrology
1997 Young Scientist Award, American Society of Transplant Physicians
2002 Interurban Clinical Club
2003 Association of American Physicians
2005 Basic Science Established Investigator Award, American Society of Transplantation

Part II: Research, Teaching, and Clinical Contributions

A. Narrative Report of Research, Teaching, and Clinical Contributions:

The long-term goal of the laboratory is to enable the development of new approaches and strategies for the induction of tolerance in transplantation and autoimmune diseases, thereby enabling patients to dispense with the need for long-term immunosuppressive drugs and their attendant complications. The approach we have taken is to utilize mouse models of these disorders to identify potential barriers to tolerance and explore ways to overcome them. We have also used these models, when appropriate, to investigate basic questions in T cell immunobiology. Work in our laboratory over the past two decades has led, among other things, to: the FDA approval of Orencia (Abatacept) for the treament of rheumatoid arthritis; and phase III clinical trials of Belatacept for prevention of renal transplant rejection. More recently, we have created the paradigm that transplant tolerance generally requires the widescale deletion of alloreactive T cells, but that unbiased deletion of all cells actually can be a barrier to tolerance, a concept which has guided the development of new clinical trials. As Deputy Director of the NIH funded Immune Tolerance Network, a consortium for phase I/II trials in autoimmunity, allergy, and transplantation, we have established a series of biomarker core groups which perform detailed mechanistic assays for all of the trials. This work has provided detailed mechanistic insight into the mechanisms of success of many new immunomodulatory agents. Lastly, work as Editor in Chief of the *Journal of Clinical Investigation*, provides leadership and service to the biomedical research community.

B. Funding Information:

Current Funding

2007-2012	NIH PO1-AI-041521 - Principal Investigator and Project Leader; “Costimulation and Cytokines in Tolerance”
2009-2011	NIH 2-PO1-AI43620 Project #2 – Project Leader; (Program Director: Y. Choi); “Molecular and cellular regulation of tolerance”,
2009-2011	NIH 2-PO1-AI43620 Project #3 – Project Co-Leader; (Program Director: Y. Choi); “Regulation of T cell fates by cytokine receptors”
2005-2010	NIH RO1-AI037691 Principal Investigator; “T cell activation death and memory in alloimmune responses”
2005-2010	NIH RO1-AI062789 - Principal Investigator; “Expression and function of the TLRs on T cells”
2006-2011	NIH RO1-AI064909 Co-Investigator; (Principal Investigator: Y. Choi); “TRAF6 and the fate of T cells”
2009-2011	Childrens Hospital of Philadelphia R21 – Co-Investigator; (Principal Investigator: S. Gallucci); “Dendritic Cell Ligation of Complement Receptor 3 in Transplantation Tolerance”
2009-2014	NIH NO1-AI-015416 – Subcontract Principal Investigator (PI – Jeffrey Bluestone); “The Collaborative Network for Clinical Research in Immune Tolerance
2010-2011	Juvenile Diabetes Research Foundation – Subcontract Principal Investigator (PI – Diane Mathis); “Role of the CD226 Pathway in type I diabetes”
2009-2014	NIH UO1 AI-063623, - Co-Investigator (Project Director, Mohamed Sayegh) “Novel Therapies of Chronic Allograft Dysfunction (Co-Investigator)
2010-2011	Helmsley Foundation – Co-Principal Investigator, “Pilot Projects in type 1 diabetes and Crohn’s disease”

Pending Funding

2010-2015 NIH RO1-AI037691 Principal Investigator; "T cell activation death and memory in alloimmune responses"
2010-2015 NIH RO1-AI062789 - Principal Investigator; "Expression and function of the TLRs on T cells"
2011-2016 NIH RO1-AI33045 – Co-Principal Investigator; "Distinguishing induced and natural regulatory T cell roles in transplant tolerance"

Past Funding

1988-1993 NIH Clinical Investigator Award Principal Investigator; "Suppressor Cells in Renal Transplantation"
1993-1998 NIH RO1 CA61225 Principal Investigaor; "B7 Gene Transfer for Immunotherapy of Breast Cancer"
1993-1998 NIH RO1-DK44737 Principal Investigator; "Accessory Molecules in Thymic Maturation"
1995 NIH Shared Equipment Grant Principal Investigator; "FACScan-4 and Sort Acceleration Modification for FACStar Plus"
1995-2000 NIH RO1-AI037691 Principal Investigator; "Tolerance Induction by DST and Costimulatory Blockade"
1997-2002 NIH PO1-AI-041521 - Principal Investigator and Project Leader; "Costimulation and Cytokines in Tolerance"
1999-2004 NIH 2-PO1-AI43620 Project #2 – Project Leader; (Program Director: Y. Choi); "Molecular and cellular regulation of tolerance",
2000-2005 NIH RO1-AI037691 Principal Investigator; "Tolerance Induction by DST and Costimulatory Blockade"
2000-2005 NIH/NIDDK T32-DK07006 Co-Investigator; Renal Research Training Program
2002-2006 University of California-San Francisco NO1-AI-15416 Co-Investigator; (Program Director: J. Bluestone); "Immune Tolerance Network"
2002-2007 NIH PO1-AI-041521 - Principal Investigator and Project Leader; "Costimulation and Cytokines in Tolerance"
2004 NIH RO1- AI059008-01 Principal Investigator "Regulation of Suppressor Cells by PTEN"
2004-2009 NIH 2-PO1-AI43620 Project #2 – Project Leader; (Program Director: Y. Choi); "Molecular and cellular regulation of tolerance",
2004-2006 NIH R21-HL79450-01 Principal Investigator; "Homeostatic T Cell Expansion as a Barrier to Tolerance"
2005-2006 NIH RO1-AI047257-03 Principal Investigator; "APCs in Chronic Heart Rejection"
2004-2009 NIH RO1-AI-044264 – Co-Investigator; (Principal Investigator: Y. Choi); "A novel cytokine that promotes dendritic cell survival"
2004-2009 NIH UO1-AI-063589 Co-Investigator; (Program Director: A. Shaked); "Molecular Profiling and Immunomodulatory Interventions
2005-2010 NIH/NIDDK T32-DK07006 Principal Investigator; Renal Research Training Program

C. Report of Current Research Activities:

Project

Our laboratory focuses on basic and translational investigations of T cell immunobiology with a particular interest in transplantation biology and autoimmunity. Through investigations into T cell development, T cell memory, regulatory T cells, and the role of

inflammatory signals in shaping T cell immune responses, we aim to develop a deeper understanding of processes relevant to T cell mediated immune responses in vivo, with a goal towards developing new approaches to therapy and new means to monitor the success of those approaches.

Bench research

1. Role of the tumor suppressor gene *Pten* in T cell homeostasis. a. Conditional deletion of the lipid phosphatase *Pten* in foxp3 regulatory T cells. The development of Foxp3 regulatory T cells is enhanced by agents which block PI3 kinase and/or its downstream signals. Through the genetic ablation of the PI3 kinase regulator *Pten* using *Pten*-floxed mice and foxp3-Cre mice, we will examine how enhanced PI3 kinase signaling affects the homeostasis and function of established regulatory T cells and influences susceptibility to autoimmunity. b. Functions of PTEN required to prevent lymphoma and autoimmunity. Using knock-in mice with targeted mutations of *Pten* we will examine whether the lipid phosphatase domain, the nuclear CENP-C binding function, or both, are required to block the development of T cell malignancy and autoimmunity, thus defining the mechanism(s) by which this gene acts.

2. Conditional deletion of *CD28* in effector and regulatory T cells. CD28 is known to be a critical costimulatory molecule for naïve T cells. We have used Bac recombineering to generate mice with floxed CD28. We plan to investigate its role in effector and regulatory T cells by crossing the CD28-floxed mice we develop with granzymeB-Cre and foxp3-Cre mice respectively. These studies will use models of transplantation and infection. Additional studies will utilize temporal deletion of CD28 under a tamoxifen-inducible Cre to determine the function(s) and role(s) of CD28 in an ongoing response.

3. Role of T cell expressed MyD88 in transplantation tolerance. Preliminary data indicates that lack of MyD88 in T cells may prevent the induction of transplantation tolerance. We are exploring the concept that MyD88 is required for T cell survival and regulatory T cell conversion.

4. Role of T cell expressed MyD88 in LCMV infection, viral clearance, induction of memory, and exhausted T cells. We have shown that MyD88 is required for the response of naïve CD8 T cells to LCMV. Here, we will study if this adaptor protein is required for later T cell responses and the development of immunity.

Area being developed for funding

1. Signals dictating the anatomic compartmentalization of regulatory T cells
2. Genetic programs activated by MyD88 in T cells

D. Report of Teaching:

Local invited teaching presentations

TEACHING EXPERIENCE:
Medical School

1994 - 2006 Attending Physican, Renal Service, Hospital of the Unversity of Pennsylvania, University of Pennsylvania, PA
1995 - 2006 ID 205 course - lecturer and workshop, University of Pennsylvania, PA
2004 Frontiers 518 – "Transplantation Medicine", – Course Director, Univerity of Pennsylvania, PA

2009 "Transplantation Immunology" lecture in Immunology, Microbiology and Pathology course, Harvard Medical School

Graduate School
1994 - 2000 Thesis advisor for Steven Eck, Univerity of Pennsylvania, PA
1995 Advisor for rotating Immunology Graduate Student, Robert Dobele, Univerity of Pennsylvania, PA
1995 - 1996 Advisor for Four Schools Physician-Scientist Program Student, Laura Alonso, Univerity of Pennsylvania, PA
1996 - 2001 Immunology 607 Course Director, Univerity of Pennsylvania, PA
1996 - 2002 Chair, Thesis Committee for Hamid Basiri, Univerity of Pennsylvania, PA
1996 - 1998 Member, Thesis Committee for Chris Coughlin, Univerity of Pennsylvania, PA
1996 - 1998 Member, Thesis Committee for Holly Kurzawa, Univerity of Pennsylvania, PA
1996 Advisor for rotating Immunology Graduate Student, David Chang, Univerity of Pennsylvania, PA
1996 - 2002 Member, Thesis Committee for Ashlyn Eaton, Univerity of Pennsylvania, PA
1996 - 2000 Member, Thesis Committee for George Gunn, Univerity of Pennsylvania, PA
1997 Advisor for rotating Immunology Graduate Student, Hrefna Gudmundsdottir, Univerity of Pennsylvania, PA
1997 Advisor for rotating Immunology Graduate Student, Adam Schrum, Univerity of Pennsylvania, PA
1997 Advisor for rotating Immunology Graduate Student, Melissa Lerman, Univerity of Pennsylvania, PA
1997 - 2001 Thesis advisor for Hrefna Gudmundsdottir, Univerity of Pennsylvania, PA
1997 - 2002 Thesis advisor for Adam Schrum, Univerity of Pennsylvania, PA
1997 - 2000 Member, Thesis Committee for Amy Reed, Univerity of Pennsylvania, PA
1998 - 1999 Advisor for rotating Immunology Graduate Student, Steve Bensinger, Univerity of Pennsylvania, PA
1999 Advisor for rotating Immunology Graduate Student, Christina Tato , Univerity of Pennsylvania, PA
1999 - 2003 Chair, Thesis Committee for Melissa Lerman, Univerity of Pennsylvania, PA
1999 - 2001 Chair, Thesis Committee for Audrey Park, Univerity of Pennsylvania, PA
1999 - 2001 Member, Thesis Committee for Thomas Liu, Univerity of Pennsylvania, PA
2000 Advisor for rotating Immunology Graduate Student, Maria Lemos, Univerity of Pennsylvania, PA
2000 - 2001 Chair, Thesis Committee for Steve Bensinger, Univerity of Pennsylvania, PA
2000 - 2002 Member, Thesis Committee for Aaron Neumann, Univerity of Pennsylvania, PA
2000 - 2002 Member, Thesis Committee for James Chung, Univerity of Pennsylvania, PA
2001 - 2005 Member, Thesis Committee for Maria Lemos, Univerity of Pennsylvania, PA
2001 - 2005 Member, Thesis Committee for Kathryn Foulds, Univerity of Pennsylvania, PA
2001 - 2003 Thesis advisor for Steve Bensinger, Univerity of Pennsylvania, PA
2001 - 2007 Member, Thesis Committee for Stacey Garrett, Univerity of Pennsylvania, PA
2002 - 2005 Thesis advisor for Aaron Neumann, Univerity of Pennsylvania, PA
2002 - 2006 Thesis advisor for Andrew Gelman, Univerity of Pennsylvania, PA
2002 – 2005 Member, Thesis Committee for Kenneth Lee, Univerity of Pennsylvania, PA
2002 Advisor for rotating Immunology Graduate Student, Ben Schwartz, Univerity of Pennsylvania, PA

2003	Advisor for rotating Immunology Graduate Student, Thi Bui, Univerity of Pennsylvania, PA
2003	Advisor for 4th yr. Med Student research elective, Jessica Wang, Univerity of Pennsylvania, PA
2004 - 2009	Immunology 605 Course Director, Univerity of Pennsylvania, PA
2004	Advisor for rotating Immunology Graduate Student, Jodi Buckler, Univerity of Pennsylvania, PA
2004 - 2008	Thesis advisor for Jodi Buckler, Univerity of Pennsylvania, PA
2005	Advisor for rotating Immunology Graduate Student Soyoung Oh, Univerity of Pennsylvania, PA
2005	Advisor for rotating Immunology Graduate Student Hilda Ramon, Univerity of Pennsylvania, PA
2005	Advisor for rotating Immunology Graduate Student Adeeb Rahman, Univerity of Pennsylvania, PA
2005	Advisor for rotating Immunology Graduate Student Paige Porrett, Univerity of Pennsylvania, PA
2005 - 2008	Member, Thesis Committee for Fred Karnell, Univerity of Pennsylvania, PA
2005	Member, Thesis Committee for Soyough Oh, Univerity of Pennsylvania, PA
2005 - 2008	Member, Thesis Committee for Megan Suhoski, Univerity of Pennsylvania, PA
2005 - 2007	Member, Thesis Committee for Carolyn Clark, Univerity of Pennsylvania, PA
2005 -	Thesis advisor for Adeeb Rahman, Univerity of Pennsylvania, PA
2005 - 2008	Thesis advisor for Hilda Ramon, Univerity of Pennsylvania, PA
2006 - 2008	Thesis advisor for Paige Porrett, Univerity of Pennsylvania, PA
2008	Advisor for rotating Immunology Graduate Student Aisling O'Hara, Univerity of Pennsylvania, PA
2009	Member, Thesis Committee for Aisling O'Hara, University of Pennsylvania, PA
2010	Thesis Examiner, Roselynn Eumira Rodriguez-Manzanet, Harvard University

Advisory and Supervisory Responsibilities in Clinical or Laboratory Setting:
1990-Present Principle Investigator (PI), T Cell Immunobiology Laboratory

Names of Advisees or Trainees:

Past Trainees:	**Type**	**Start /End Years**	**Degree (s)**	**Year**	**School**	**Project Title**	**Current Title**
Tang, A.	Post	1994-1996	M.Sc.	1988	Nanjing Medical College	Role of costimulation in contact hypersensitivity	Research Associate, Merck, West Point, PA
Eck, S.	Pre	1994-2000	B.Sc.	1991	Univ. of DE	Mechanism of tolerance to a self-tumor antigen	Junior Scientist, Therakos, Malvern, PA
Wells, A.	Post	1996-2000	Ph.D.	1996	Univ. of Wisconsin-Madison	Effects of antigen concentration and costimulatory signals on T cell proliferation and survival	Asst. Professor of Pathology, U. Penn
Gudmundsdottir, H.	Pre	1997-2001	M.D.	1988	Univ. of Iceland	Functional analysis of T cell differentiation and proliferation in vivo	Univ. of Iceland
Schrum, A.	Pre	1997-2002	M.Sc.	1996	Brigham Young Univ.	Regulation of TCR expression through CD28	Asst. Professor, Mayo Clinic
Sankaran, D.	Post	1999-2001	Ph.D.	1998	Univ. of Manchester	IL-2R signal transduction in anergic T cells	Sydney Australia
Adler, S.	Post	1999-2003	M.D.	1995	Univ. of MD	Control of responses through retroviral transduction of cell-cycle regulatory genes	GlaxoSmith Kline

Mata, M.	Post	1999-2002	Ph.D.	1999	Univ. of PA	Control of T cell responses through retroviral transduction of cell-cycle regulatory genes	Centecor, Malvern, PA
Langmuir,P.	Post	2000-2002	M.D.	1994	Yale Medical School	Studies of alloreactive T cells using BMT models	AstraZeneca
Bensinger, S.	Post	1998-2003	V.MD	1998	Univ. of PA	Immunobiology Trags	Assistant Professor, UCLA
Chiffoleau, E.	Post	2002-2003	Ph.D.	2002	Univ. of Nantes	Mechanisms of allograft tolerance in rats	Laboratory Head, INSERM, Univ. of Nantes, France
Neujhar, D.	Post	2004-2005	M.D.	2000	Cornell Univ,	Role of homeostatic proliferation in transplant rejection	Asst. Professor, Emory School of Medicine
Chen, C.	Post	2002-2005	Ph.D.	2002	Sun-see Univ.	Homeostatic T cell Tolerance	China
Gelman, A.	Pre	2003-2006	BSc	1996	Univ. of CA	Toll like receptors function in T cell Immune Responses	Asst. Professor, Washington Univ. School of Med.
Walsh, P.	Post	2001-2006	Ph.D.	2001	Univ. of Cork	Ox-20 in T cell responses	Lecturer, Trinity College (Dublin)
Yang, J.	Post	2004-2006	M.D.	1995	Seoul Natl Univ.	The role of TRAP6 in T cell	Asst. Professor, Gacheon U. of Medicine and Science, Inchon, Korea

Hickman, S.	Post	2003-2007	Ph.D.	2003	Temple	Signaling Mechanisms of Regulatory T cells	Scientific Writer, IOMAI Corporation
Taylor, D.	Post	2004-2007	Ph.D.	2003	City Univ. NY	The Role of STATS and Pim kinase in Regulatory T-cell homeostasis	MedImmune
Karnell, J,	Pre	2004-2008	B.Sc.	2001	Univ. of Penn.	The role of PTEN in regulating TCR responsiveness	MedImmune
La Rosa, D.	Post	2004-2008	M.D.	2000	SUNY	The role of MYD88 in cell responses	Asst. Professor, U. Penn
Porrett, P.	Pre	2005-2008	M.D.	2001	Northwestern Univ.	TLR ligand effects on natural & adoptive Tregs	Surgical Resident, U. Penn.
Rahman, A.	Pre	2005-2009	B.Sc.	2004	Brown Univ.	The role of MyD88 in T cells in infection	Post-doc, UNC, Jenny Ting's Lab
Blosser, C	Post	2008-2010	M.D.	2002	Univ. of Michigan	T cell expressed MyD88 in Transplantation	Assistant Professor, Univ. of Iowa
Harris, J	Post	2008	M.D./ Ph.D.	2004	UMass	Visualization of T cells during autoimmune vitiligo	Assistant Professor, Univ. of Massachusetts
Liu, X.	Post	2007-	Ph.D.	2007	Thomas Jefferson Univ.	Regulation of Suppressor Cells by PTEN	
CURRENT							
Zhang, R.	Post	2008-	Ph.D.	2008	Univ. of Minnesota	Conditional gene targeting of CD28	Still in training
Lieberman, S	Post	2008-	M.D./ Ph.D.	2004	Albert Einstein	Anatomic Specialization of Regulatory T cells	Still in training

Murphy, S	Post	2010	PhD	2006	Brown	Role of MyD88 in T cell responses to LCMV	Still in training
Beom Kim	Post	2010	MD	1994	Yonsei Univ. College of Medicine	Role of MyD88 in T cell responses to alloantigen	Still in training
Yu Lu	Post	2010	PhD	2009	Institute of Biophysics, Chinese Academy of Sciences	PTEN in lymphomagenesis and autoimmunity	Still in training
Natavudh Townamchai	Post	2010	MD	2001	Chiang Mai University	Renal transplant tolerance	Still in training

INVITED LECTURER/SPEAKER:

1994

April, 1994	"T Cell Costimulation in Immune Responses", Harvey I. Werber Memorial Lectureship, Case Western Reserve Univ., Clevelyand, Ohio
May, 1994	"Novel Strategies for Tolerance Induction", Basic Science Symposium, American Society of Transplant Physicians Annual Meeting, Chicago, IL
May, 1994	"T Cell Costimulation in Immune Responses", Wayne State U., Detroit, MI
October, 1994	"The Role of Costimulatory T Cell Activation Pathways in Allorecognition", Plenary Lecture, Annual Meeting of the American Society for Histocompatibility and Immunogenetics.

1995

February, 1995	"Apoptosis and the Immune Response", Annual Meeting of the American Academy of Allergy and Immunology, New York, NY
April, 1995	"Transplant Tolerance Through Blockade of T Cell Costimulation", Univ. of Chicago, Chicago, IL
April, 1995	"Inducing Tolerance Through Blockade of Costimulatory Signals", McGill Univ., Montreal, QUE, Canada
June, 1995	"Overview of Tolerance". Williamsburg Meeting of the Cystic Fibrosis Foundation. Williamsburg, VA
September, 1995	"The Effect of Costimulatory Blockade on the Fate and Function of Antigen-Reactive Cells in Vivo", Department of Pathology, Univ. of Michigan, Ann Arbor, MI
October, 1995	"Accessory Molecules of T cell activation, role of CD28", Second Intl. Symposium on Transplant Tolerance, Bergamo, Italy.
November, 1995	"Costimulation Therapy in Transplantation", Basic Science Symposium of the American Society of Nephrology, San Diego, CA
November, 1995	"The Effect of Costimulatory Blockade on the Fate and Function of Antigen-Reactive Cells in Vivo", Department of Pathology, New York Univ., New York, NY
November, 1995	"Blocking Costimulatory Signals for In Vivo Immunosuppression", Genetics Institute, Cambridge, MA.

1996

March, 1996	"T and B Cell Costimulation", Annual Meeting of the North American Pediatric Renal Transplant Cooperative Study, Washington, DC.
March, 1996	"Immunosuppression for Transplantation: Second Signals are of Primary Importance", Renal Division, Duke Univ., Raleigh, NC
April, 1996	"Immunosuppression Through Blockade of T Cell Costimulation", Renal Division, Mt. Sinai School of Medicine, New York, NY
May, 1996	"Role of Costimulatory Signals in T Cell Immune Responses", Immunology Council, Johns Hopkins Univ., Baltimore, MD
October, 1996	"Costimulatory Signals in T Cell Immune Responses", Memorial Sloan Kettering Institute, New York, NY.
December, 1996	"Costimulatory Signals in T Cell Immune Responses", Smith-Kline Beecham, King of Prussia, PA.

1997

January, 1997	"Costimulatory Pathways in Graft Rejection", Keystone Symposium on Immunologic Aspects of Cardiovascular Diseases, Keystone, CO.
January, 1997	"The Role of T Cell Costimulation During In Vivo Immune Responses", Univ. of Pittsburgh Cancer Institute, Pittsburgh, PA.
April, 1997	"Tolerance Induction Through Costimulatory Blockade", Conference on Active Immunization for Autoimmune and Infectious Diseases, Fondation Marcel Mérieux, Veyrier-du-Lac, France.
May, 1997	"The Role of T Cell Costimulation During In Vivo Immune Responses", Dupont-Merck, Wilmington, DE.

September, 1997 "Trends in Biologic Immunosuppression", Fifth Basic Sciences Symposium of the Transplantation Society, Chatauqua, NY.

November, 1997 "T Cell Costimulation: Applications in Tumor Immunology", National Cancer Institute of Thailand, Bangkok, Thailand.

1998

March, 1998 "Single Cell Analyses of T Cell-Mediated Immune Responses", Massachusetts General Hospital Immunology Seminar Series, Boston, MA.

March, 1998 "The Role of Costimulatory Signals in T Cell Mediated Immune Responses", Bristol-Myers Squibb, Princeton, NJ.

June, 1998 "The Role of Costimulatory Signals in Transplant Rejection and Related Immune Responses", NIAID Council, Bethesda, MD

July, 1998 "Single Cell Analysis of In Vivo T Cell Responses: Role of Costimulatory Signals", International Congress of The Transplantation Society, Montreal, QUE, Canada.

October, 1998 "Role of Costimulatory Signals: CD28/B7 and CD40:CD40L", American Society of Nephrology Annual Meeting, Philadelphia, PA.

November, 1998 "Role of Costimulatory Signals During T Cell-Mediated Immune Responses: Implications for Transplantation", Imperial College Transplantation Symposium, London, UK

December, 1998 "Role of Costimulatory Signals During T Cell-Mediated Immune Responses", Repligen Corporation, Needham, MA

1999

January, 1999 "Single Cell Analysis of In Vivo T Cell Responses: Role of Costimulatory Signals", 5th International Tolerance Symposium, Breckenridge, CO.

March, 1999 "Clonal Expansion and Clonal Deletion in T Cell Responses", Keystone Symposium on Molecular and Cell Biology of Transplantation, Incline Village, NV

April, 1999 "Clonal Expansion and Clonal Deletion in T Cell Responses", Cancer Center Grand Rounds, Univ. of Minnesota, Minneapolis, MN

May, 1999 "Clonal Expansion and Clonal Deletion in T Cell Responses", Renal Grand Rounds, Emory Univ., Atlanta, GA

September, 1999 "Induction of Transplantation Tolerance by Donor Antigen plus Costimulatory Blockade", American Association of Blood Banks/NHLBI Scientific Think Tank, Ellicott City, MD.

November, 1999 "Transplantation Tolerance: A Matter of Life and Death", American Society of Nephrology Annual Meeting, Miami Beach, FL.

December, 1999 "Requirement For T Cell Apoptosis In The Induction Of Peripheral Transplantation Tolerance", Biogen, Boston, MA.

2000

March, 2000 "Requirement For T Cell Apoptosis In The Induction Of Peripheral Transplantation Tolerance", Canadian Society of Transplantation, Mont Tremblant, QUE, Canada.

March, 2000 "Requirement For T Cell Apoptosis In The Induction Of Peripheral Transplantation Tolerance", Johns Hopkins Univ., Baltimore, MD.

April, 2000 "Transplantation Tolerance: A Matter of Life and Death", Wyeth-Ayerst Pharmaceuticals, Radnor, PA.

May, 2000 "Transplantation Tolerance: A Matter of Life and Death", Stanford Univ., Transplant Immunology Program, Stanford, CA.

May, 2000 "Transplantation Tolerance: Lessons Learned From Small And Large Animals", Transplant 2000, Chicago, IL.

August, 2000 "T Cell Activation", 1st Congress of the International Pediatric Transplantation Association, Venice, Italy

August, 2000 "Clonal Expansion and Clonal Deletion in T Cell Responses", 18th International Congress of the Transplantation Society, Rome, Italy

September, 2000 "Clonal Expansion and Clonal Deletion in T Cell Responses", Trinity College, Oxford Univ., Oxford, UK.

November, 2000 "Transplantation Tolerance: A Matter of Life and Death", Visiting Research Professor, Transplantation and Immunology Day, Univ. of Toronto, Toronto, ON.
December, 2000 "Transplantation Tolerance: A Matter of Life and Death", Immunology Research Program, Univ. of Michigan, Ann Arbor, MI.

2001

January, 2001 "The Promise and Challenge of Transplantation Tolerance", Renal Grand Rounds, Vanderbilt Univ., Nashville, TN
March, 2001 "Transplantation Tolerance: A Matter of Life and Death", Renal Grand Rounds, Univ. of Colorado, Denver, CO
March, 2001 ""Transplantation Tolerance: Lessons Learned From Small And Large Animals", Controversies in Transplantation, Breckenridge, CO
April, 2001 "Transplantation Tolerance: A Matter of Life and Death", Annual Meeting of American Association of Immunogists, Orlando, FL
April, 2001 "The Promise and Challenge of Transplantation Tolerance", Distinguished Visiting Professor, Medicine Grand Rounds, Duke Univ., Durham, NC
April, 2001 "Transplantation Tolerance: A Matter of Life and Death", Immunobiology Seminar Series, Yale Univ., New Haven, CT
June, 2001 "Transplantation Tolerance: A Matter of Life and Death", Combined Transplantation Immunology Program, Cornell Univ. and Columbia Univ., New York, NY
September, 2001 "Tolerance", Mexican Society of Transplantation Annual Meeting, Ixtapa, Mexico.
November, 2001 "Transplantation Tolerance: Lessons for Autoimmunity", Annual Autoimmunity Symposium, Harvard Univ., Boston, MA

2002

January, 2002 "Clonal Deletion in Transplantation Tolerance", 7th International Zuers Symposium on Kidney Transplantation, Zuers, Austria
April, 2002 "Clonal Size Restriction In Tolerance,", Keystone Symposia on "Immunologic Diseases and Tolerance", Steamboat Springs, CO.
June, 2002 "Clone Size and Transplant Tolerance, FASEB conference on "Transplantation Immunology", Saxtons River, VT.
June, 2002 "Tolerance in Transplantation", 9th Annual NAT Conference on Transplantation, INSERM, Nantes, France
September, 2002 "Transplantation Tolerance: A Matter of Life and Death", Baylor Institute for Immunology, Dallas, TX
October, 2002 "T Cell Activation and Tolerance", Univ. of Pittsburgh Diabetes Center, Pittsburgh, PA
November, 2002 "Challenges and Opportunities for Tolerance", Harvard Univ./Juvenile Diabetes Foundation Research Center, Boston, MA
November, 2002 "Tolerance in Transplantation", Committee on Immunology, Univ. of Chicago, Chicago, IL.

2003

January, 2003 "Promises and Barriers for Transplantation Tolerance", Univ. of Maryland Transplant Program, Baltimore, MD
February, 2003 "Apoptosis and Transplantation Tolerance", 4th International Workshop on Non-myeloablative Stem Cell Transplantation, Southampton, Bermuda.
March, 2003 "The Promise and Challenge of Transplantation Tolerance", John P. Peters Visiting Professor, Medical Grand Rounds, Yale Univ., New Haven, CT.
March, 2003 "Checkpoints Regulating T Cell Responses", Renal Grand Rounds, Yale Univ., New Haven, CT
April, 2003 "T Cell Quantity and History Regulate Tolerance Susceptibility", Transplant Society of Australia and New Zealand, Canberra, ACT, Australia.
September, 2003 Homeostatic Proliferation, Deletion, and Tolerance", 4th Dusseldorf Symposium on Immunotoxicology, Dusseldorf, Germany
October, 2003 "Deletional Tolerance", International Xenotransplantation Congress; Glasgow, United Kingdom.

November, 2003 "Control of T Cell Responses", ASN Basic Science Research Conference
"Autoimmunity and Tolerance in Organ Injury, San Diego, CA

2004

February, 2004 "Homeostatic Proliferation is a Barrier to Tolerance", 6th International Conference on New Trends in Immunosuppression, Salzburg, Austria.

March, 2004 "Barriers to Transplantation Tolerance", Dept. of Immunology Charles Gould Easton Seminar Series, Univ. of Toronto, Toronto, ONT, Canada

April, 2004 "Why is Tolerance So Hard to Achieve?", La Jolla Institute for Allergy and Immunology, La Jolla, CA

June, 2004 "Why is Tolerance So Hard to Achieve?", New York Univ. Immunology Club, New York, NY

June, 2004 "Regulating Regulatory T cells Through PTEN", FASEB Summer Research Conference on Transplantation Immunology, Snowmass, CO.

September, 2004 ""Regulating Regulatory T cells Through PTEN", National Institutes of Health, Immunology Interest Group, Bethesda, MD.

2005

February, 2005 "Regulating T cell Responses Through PTEN", Harvard Program in Immunology, Boston, MA

June, 2005 "Control of T cell Responses – New Roles for Old Molecules", 9th Basic Science Symposium of the Transplantation Society, La Baule, France

June, 2005 "Expression and Function of TLRs on T Cells", Imperial College of Medicine, London, England

November, 2005 "Homeostatic Proliferation as a Barrier to Tolerance", Annual Meeting of the American Society of Nephrology, Philadlephia, PA.

November, 2005 "Expression and Function of TLRs on T Cells", Univ. of Minnesota Immunology Center, Minneapolis, MN

2006

January, 2006 "Barriers to Tolerance", Beth Israel-Deaconess Transplant Center, Boston, MA

February, 2006 "Expression and Function of TLRs on T Cells", 7th International Conference on New Trends in Immunosuppression, Berlin, Germany

March, 2006 "Barriers to Tolerance", Guy's Hospital Symposium on Transplantation, Kings College of Medicine, London, UK

May, 2006 "Immunology of Costimulation Blockade", Bristol-Myers Squibb, Lawrenceville, NJ

July, 2006 "Barriers to Transplantation Tolerance", Columbia Univ., New York, NY

July, 2006 "What's Hot", World Transplant Congress, Boston, MA

October, 2006 "Prospects for Immune Tolerance", Transplantation Grand Rounds, Columbia Univ., New York, NY

November, 2006 "Expression and Function of TLRs on T Cells", Merck Research Laboratories, Rahway, NJ

2007

January, 2007 "Barriers to Tolerance", Univ. of Maryland Immunobiology and Transplantation Immunology Seminar Series, Baltimore, MD

March, 2007 "Regulatory T cells and Cancer Immunity", Cancer 2007, Hong Kong.

March, 2007 "Interplay of Memory and Regulatory T Cells", 4th Cellular Therapy Symposium", Regensberg, Germany

May, 2007 "Memory T Cells and Tolerance Induction, American Transplant Congress, San Francisco, CA

June, 2007 "Transplantation Tolerance: Moving the Bench to the Bedside", Inaugural Address, Biomedical Research Forum, Guys-St. Thomas Biomedical Research Centre, London, UK

September, 2007 "Expression and Function of MyD88 and TLRs on T cells", Autoimmunity: From Bench to the Clinic, Trinity College, Oxford Univ., Oxford, UK

2008

February, 2008 "Expression and Function of MyD88 and TLRs on T cells", Keystone Meeting on Tolerance in Transplantation and Autoimmunity, Keystone, CO.

March, 2008 "Immune Tolerance: From Mice to Molecules to Man", Oswald T. Avery Memorial Lecture, Colgate Univ., Hamilton, NY

April, 2008 "Expression and Function of MyD88 and TLRs on T cells", Duke Univ. Dept. of Immunology, Durham, NC

April, 2008 "Expression and Function of MyD88 and TLRs on T cells", Univ. of North Carolina Lineberger Cancer Center, Chapel Hill, NC

May, 2008 "Expression and Function of MyD88 and TLRs on T cells", GlaxoSmithKline, Upper Providence, PA

June, 2008 "Developing Assays to Measure Tolerance, American Transplant Congress, Toronto, ON

July, 2008 "Inflammation and Regulation", FASEB Summer Research Conference on Transplantation Immunology, New Haven, CT

July, 2008 "The Most Promising New Strategies for Tolerance", American College of Reconstructive Transplant Surgery, Philadelphia, PA

September, 2008 "Inflammaton and Regulation in Transplantation Tolerance", Univ. of Pittsburgh Starzl Transplant Center Grand Rounds, Pittsburgh, PA

November, 2008 "Transplantation Tolerance – Trying Not to Get Lost in Translation", Plenary Lecture, The Elliot Newman Society Retreat, Vanderbilt Univ., Nashville, TN

December, 2008 "Transplantation Tolerance – Trying Not to Get Lost in Translation", Human and Translational Immunology Seminar Series, Yale Univ., New Haven, CT

2009

February, 2009 "Innate Immunity in Tolerance and Rejection", Plenary Lecture, Swiss Transplant Society, Interlaken, Switzerland

March, 2009 "PTEN: A Tumor Suppressor Gene that Regulates T Cell Functions and Homeostasis", London Immunology Group, British Society for Immunology, London, UK

March, 2009 "The Interplay of Memory, Regulation and Inflammtion in Transplantation", Joint meeting of the Basic Sciences Symposium of the Transplant Society and the European Society of Transplantation, Brussels, Belgium

May, 2009 "PTEN: A Tumor Suppressor Gene that Regulates T Cell Functions and Homeostasis", 3rd Annual Bice Perussia Symposium, Thomas Jefferson Univ. School of Medicine, Philadelphia, PA

May, 2009 "Transplantation Tolerance: Translating Knowledge into Progress", Transplant Biology Research Center, Massachusetts General Hospital, Boston, MA

December, 2009 "Biomarkers of Renal Transplantation Tolerance", Biogen-Idec Tolerance Initiative, Cambridge, MA

2010

March, 2010 "The Role of Regulation in Transplantation Tolerance", Plenary Lecture, American Academy of Allergy, Asthma and Immunology, New Orleans, LA

May, 2010 "Costimulatory Requirements of Memory T Cells", American Transplant Congress, San Diego, CA

May, 2010 "Reforming Scientific Thinking – 10 years of the ATC", American Transplant Congress, San Diego, CA

June, 2010 "Regulation of T Lymphocytes by Innate Immune Pathways, Plenary Lecture, Keystone Meeting on Innate Immunity, Trinity College, Dublin, Ireland

July, 2010 "Expression and Function of PTEN in T Cells", Chinese Academy of Sciences, Institute of Zoology, Beijing, China

July, 2010 "Biomarkers of Transplant Tolerance", Nanjing Military Hospital, Nanjing, China

July, 2010 How the JCI Works, Second International Conference on Regulatory T cells and Th17 T cells", Shanghai, China

July, 2010 "Role of the Tumor Suppressor Gene *Pten* in T cell Homeostasis", Second International Conference on Regulatory T cells and Th17 T cells", Shanghai, China

Part III: Bibliography

Original Articles:

1. Turka LA, Ramos EL, Leggat JE, Milford EL, Fraser PA, and Carpenter CB. Antigen specificity of MLR-induced suppressor cells. Hum. Immunol. 20:293-306, 1987.
2. Turka LA, Carpenter CB, Yunis EJ, and Milford EL. Differential effects of an anti-interleukin 2 receptor antibody on cytotoxic and suppressor cells. In: Dupont, B., ed. Immunobiology of HLA. New York: Springer-Verlag, p. 559, 1989.
3. Turka LA, Carpenter CB, Yunis EJ, and Milford EL. Selective sparing of suppressor cells generated in mixed lymphocyte response by an anti-interleukin-2 receptor antibody. Transplantation 47:182-188, 1989.
4. Turka LA, Tanaka K, Kupiec-Weglinski JW, Milford EL, Tilney NL, and Carpenter CB. In vivo activity of mixed lymphocyte response-generated suppressor cells and ability to prolong cardiac allograft survival in rats. Transplantation 47:388-390, 1989.
5. Turka LA, Goguen JE, Gagne JE, and Milford EL. Presensitization and the renal allograft recipient. Transplantation 47:234-240, 1989.
6. Ramos EL, Turka LA, Leggat JE, Wood IG, Milford EL, and Carpenter CB. Phenotypically defined T helper inducer cells (T4+4B4+) are decreased and T suppressor effector cells (T8+2H4+) are increased in the peripheral blood of stable renal allograft recipients. Transplantation 47:465-471, 1989.
7. Tanaka K, Turka LA, Ueda H, Diamantstein T, Milford EL, Carpenter CB, Tilney NL, and Kupiec-Weglinski JW. Selective sparing of T suppressor cells by anti interleukin-2 receptor monoclonal antibodies in vitro correlates with their therapeutic effects in vivo. Transpl. Proc. 21:475-476, 1989.
8. Turka LA, Goguen JE, Carpenter CB, and Milford EL. The effect of historical crossmatches and sensitization on renal allograft survival. Transpl. Proc. 21:696-697, 1989.
9. Carpenter CB, Goguen JE, Bradley JW, Turka LA, Cho SI, and Milford EL. HLA-B/DR Matching and Cadaver renal allograft survival in New England. Transpl Proc 21:663-664, 1989.
10. Ramos EL, Turka LA, Leggat JE, Milford EL, and Carpenter CB. T cells marked by the 2H4 antigen function in allosuppression. In: Dupont, B., ed. Immunobiology of HLA. New York: Springer-Verlag, p. 487, 1989.
11. Sayegh MH, Turka LA, Milford EL, and Carpenter CB. MLR-generated suppressor cell specificity in humans is MHC restricted. Hum Immunol. 26:281-287, 1989.
12. Guba SC, Stella G, Turka LA, June CH, Lindsten T, Thompson CB and Emerson SG. Regulation of T cell Interleukin 3 expression via the CD3 and CD28 pathways. J. Clin. Invest. 84:1701-1706, 1989.
13. Turka LA, Ledbetter JA, Lee K, June CH, and Thompson CB. CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes J. Immunol. 144:1646-1653, 1990.
14. Tanaka K, Turka LA, Kupiec-Weglinski JW, Milford EL, Ueda H, Diamantstein T, Carpenter CB, and Tilney NL. Monoclonal antibodies against the 55kD subunit of the rat IL-2 receptor do not inhibit the development of suppressor cells generated in mixed lymphocyte culture. Transplantation. 50:125-131, 1990.
15. Lee K, Taylor C, Petryniak B, Turka LA, June CH, and Thompson CB. The genomic organization and origin of mRNA heterogeneity of the human CD28 gene. J. Immunol. 145:344-352, 1990.

16. Turka LA, Dayton J, Sinclair G, Thompson CB, and Mitchell BS. Guanine ribonucleotide depletion inhibits T cell activation: Studies on the mechanisms of action of the immunosuppressive drug mizoribine. J. Clin. Invest. 87:940-948, 1991.
17. Turka LA, Linsley PS, Paine R III, Schieven GL, Thompson CB, and Ledbetter JA. Signal transduction via CD4, CD8 and CD28 in immature thymocytes: Implications for thymic selection. J. Immunol. 146:1428-1436, 1991.
18. Turka LA, Schatz DG, Oettinger MA, Chun JJM, Gorka C, Lee K, McCormack WT, and Thompson CB. Thymocyte expression of the recombination activating genes RAG-1 and RAG-2: Termination by T-cell receptor crosslinking. Science. 253:778-781, 1991.
19. Paine R, Mody CH, Chavis A, Spahr MA, Turka LA, and Toews GB. Alveolar epithelial cells block lymphocyte proliferation in vitro without inhibiting activation. Am. J. Resp. Cell Mol. Biol. 5:221-229, 1991.
20. Turka LA, Kanner SB, Schieven GL, Thompson CB, and Ledbetter JA. CD45 modulates TCR/CD3-induced activation of human thymocytes via regulation of tyrosine phosphorylation. Eur. J. Immunol. 22:551-557, 1992.
21. Vandenberghe P, Freeman GJ, Nadler LM, Fletcher MC, Kamoun M, Turka LA, Ledbetter JA, Thompson CB, and June CH. Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells. J. Exp. Med. 175:951-960, 1992.
22. Danish R, El-Awar O, Weber B, Langmore J, Turka L, Ryan J, and Clarke M. C-myb effects on kinetic events during mel cell differentiation. Oncogene 7:901-907, 1992.
23. Dayton JS, Turka LA, Thompson CB, and Mitchell BS. Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism. Molecular Pharmacology 41:671-676, 1992.
24. Paine R, Chavis A, Gaposchkin D, Christensen P, Mody CH, Turka LA, and Toews GB. A factor secreted by a human pulmonary alveolar epithelial-like cell line blocks T cell proliferation between G1and S phase. Am. J. Resp. Cell Mol. Biol. 6:658-666, 1992.
25. Turka LA, Fletcher MC, Craighead N, Thompson CB, and June CH. Defective signal transduction by the CD2 molecule in immature TCR/CD3- thymocytes. Proc. Natl. Acad. Sci. U.S.A. 89:8706-8710, 1992.
26. Gratiot-Deans J, Keim D, Strahler JR, Turka LA, and Hanash S. Differential expression of Op18 phosphorprotein during human thymocyte maturation. J. Clin. Invest. 90:1576-1581, 1992.
27. Bolling SF, Turka LA, Wei R, Linsley PS, Thompson CB, and Lin H. Inhibition of B7-induced CD28 T cell activation with CTLA4Ig prevents cardiac allograft rejection: Evidence for co-stimulation. Surgical Forum 43:413-415, 1992.
28. Wu B-Y, Hanley E, Turka, LA, and Nabel GJ. Isolation of cDNA clone encoding a lineage-specific zinc finger protein. Blood 80:2571-2576, 1992.
29. Green JM, Turka LA, June CH, and Thompson CB. CD28 and staphylococcal enterotoxins synergize to induce MHC-independent T-cell proliferation. Cell. Immunol. 145:11-20, 1992.
30. Turka LA, Linsley PS, Lin H, Brady W, Leiden JM, Wei R-Q, Gibson ML, Zheng X-G, Myrdal S, Gordon D, Bailey T, Bolling SF, and Thompson CB. T cell activation by the CD28-ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad. Sci. 89:11102-11105, 1992.
31. Hanash S, Strahler J, Chan Y, Kuick, R, Teichroew D, Neel JV, Hailat N, Keim D, Dean J, Ungar D, Melhem R, Zhu XX, Andrews P, Lottspeich F, Eckerskorn C, Chu E, Ali I, Fox D, Richardson B, and Turka L. Development of a database of major human lymphoid proteins: selective constituitve expression in immature thymocytes of proliferation induced proteins. Proc. Natl. Acad. Sci. 90:3314-3318, 1993.
32. Nickoloff BJ, Mitra RS, Lee K, Turka LA, Green J, Thompson C, and Shimizu Y. Discordant expression of CD28 ligands, BB-1 and B7 on activated keratinocytes in-vitro and psoriatic cells in-vivo. Amer. J. Path. 142:1029-1040, 1993.

33. Turka LA, Gratiot-Deans J, Keim D, Green J, Bandukwala R, Strahler J, and Hanash SM. Elevated levels of PCNA in immature thymocytes: Dissociation from cell cycle progression. J. Immunol. 150:2746-2752, 1993.
34. Nickoloff BJ, Mitra R, Green J, Zheng, XG, Shimizu Y, Thompson C, and Turka LA. Accessory cell function of keratinocytes for superantigens: Dependence on LFA-1/ICAM-1 interaction. J. Immunol. 150:2148-2159, 1993.
35. Gratiot-Deans J, Ding L, Turka LA, and Nunez G. Identification of a subpopulation of human double positive thymocytes that express high levels of the bcl-2 proto-oncogene. J. Immunol. 151:83-91, 1993.
36. McCormack WT, Liu M, Postema C, Thompson CB, and Turka LA. Excision products of TCR Va recombination contain in-frame rearrangements: Evidence for continued V(D)J recombination in TCR+ thymocytes. Int. Immunol. 5:801-804, 1993.
37. Mitchell BS, Dayton JS, Turka LA, and Thompson CB. IMP dehydrogenase inhibitors as immunomodulators. From, Immunomodulatory Drugs, Ann. New York Acad. Sci. 217-224, 1993.
38. Strahler JR, Zhu XX, Hora N, Wang YK, Andrews PC, Roseman NA, Neel JV, Turka L, Hanash SM. Maturation stage and proliferation dependent expression of dUTPase in human T cells. Proc. Natl. Acad. Sci. 90:4991-4995, 1993.
39. Boise LH, González-García M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nuñez G, Thompson CB. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597-608, 1993.
40. Lin H, Bolling SF, Linsley PS, Wei R-Q, Gordon D, Thompson CB, Turka LA. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor specific transfusion. J. Exp. Med. 178:1801-1806, 1993.
41. Nestle FO, Zheng X-G, Thompson CB, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotyic and functionally distinctive subsets. J. Immunol. 151:6535-6545, 1993.
42. Nickoloff BJ, Mitra RS, Green J, Shimizu Y, Thompson C, Turka LA. Activated keratinocytes present bacterial-derived superantigens to T lymphocytes: relevance to psoriasis. J. Derm. Science. 6:127-133, 1993.
43. Green JM, Zheng XG, Shimizu Y, Thompson CB, and Turka LA. T-cell receptor stimulation, but not CD28 costimulation, is dependent on LFA-1 mediated events. Eur. J. Immunol. 24:265-272, 1994.
44. Nickoloff BJ, Nestle FO, Zheng XG, and Turka LA. T lymphocytes in skin lesions of psoriasis and mycosis fungoides express B7-1, a ligand for CD28. Blood 83:2580-2586, 1994.
45. Chan AC, van Oers NSC, Tran A, Law C-L, Turka LA, Clark EA, Guidos C, and Weiss A. Differential expression of ZAP-70 and Syk protein tyrosine kinases, and role of this family of protein tyrosine kinases in TCR signaling. J. Immunol. 152:4758-4766, 1994.
46. Goodman RM, Naidu YM, Nestle F, Green JM, Thompson CB, Nickoloff BJ, Turka LA. Keratinocyte-derived T cell costimulation induces production of IL-2 and IL-4 but not interferon-g. J. Immunol. 152:5189-5198, 1994.
47. Nestle FO, Turka LA, and Nickoloff BJ. Characterization of dermal dendritic cells in psoriasis: Autostimulation of T lymphocytes and induction of Th-1 type cytokines. J. Clin. Invest. 94:202-209, 1994.
48. Bolling SF, Lin H, Wei R-Q, Linsley P, and Turka LA. The effect of combination cyclosporine and CTLA4Ig therapy on cardiac allograft survival. J. Surg. Res. 57:60-64, 1994.
49. Nestle FO, Thompson CB, Shimizu Y, Turka LA, and Nickoloff BJ. Costimulation of superantigen-activated T lymphocytes by autologous dendritic cells is dependent on B7. Cell. Immunol. 156:220-229, 1994.
50. Nickoloff BJ and Turka LA. Immunologic functions of non-professional antigen presenting cells: New insights from studies of keratinocyte:T cell interactions. Immunol. Today 15:464-469, 1994.

51. Nickoloff BJ, Fivenson DP, Kunkel SL, Strieter RM, and Turka LA. Keratinocyte IL-10 expression is upregulated in tape stripped skin, poison ivy dermatitis, and Sezary Syndrome, but not it psoriatic plaques. Clin. Immunol. and Immunopath. 73:63-68, 1994.
52. Gratiot-Deans J, Merino R, Nuñez G, and Turka LA. Bcl-2 Expression during T cell Development: Early Loss and Late Return Occur at Specific Stages of Commitment to Differentiation and Survival. Proc. Natl. Acad. Sci. 91:10685-10689, 1994.
53. Lin H, Wei R-Q, Gordon D, Linsley P, Turka LA, and Bolling SF. Review of CTLA4Ig use for Allograft Immunosuppression. Transplant. Proc. 26:3200-3201, 1994.
54. Judge TA, Liu M, Christensen PJ, Fak JJ, and Turka LA. Cloning the rat homolog of the CD28/CTLA4-ligand B7-1: structural and functional analysis. Int. Immunol. 7:171-178, 1995.
55. Mitra RS, Judge TA, Nestle FO, Turka LA, and Nickoloff BJ. Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10: differential modulation of B7-1 (CD80) and B7-2 (CD86) expression. J. Immunol. 154:2668-2677, 1995.
56. Tewari M, Wolf FW, Seldin MF, O'Shea KS, Dixit VM, and Turka LA. Lymphoid expression and regulation of A20, an inhibitor of programmed cell death. J. Immunol. 154:1699-1706, 1995.
57. Sayegh MS, Akalin E, Hancock WW, Russell ME, Carpenter CB, and Turka LA. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J. Exp. Med. 181:1869-1874, 1995.
58. Nickoloff BJ, Turka LA, Mitra RS, and Nestle FO. Direct and indirect control of T cell activation by keratinocytes. J. Invest. Derm 105:25S-29S, 1995.
59. Khoury SJ, Akalin E, Chandraker A, Turka LA, Linsley PS, Sayegh MH, and Hancock WW. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J. Immunol. 155:4521-4524, 1995.
60. Sayegh MS, and Turka LA. T cell costimulatory pathways: Promising novel targets for immunosuppression and tolerance induction. J. Am. Soc. Nephrol. 6:1143-1150, 1995.
61. Turka LA, Goodman RE, Rutkowski JL, Sima AAF, Mitra RS, Wrone-Smith T, Toews G, Streiter RM, and Nickoloff BJ. IL-12 is contained within cutaneous peripheral nerve fibers and central and peripheral glial cells. Molecular Medicine 1:690-699 1995.
62. Judge TA, Tang A, Spain LM, Gratiot-Deans J, Sayegh MH, and Turka LA. The in vivo mechanism of action of CTLA4Ig. J. Immunol. 156:2294-2299, 1996.
63. Tang A, Judge TA, Nickoloff BJ, and Turka LA. Suppression of murine allergic contact dermatitis by CTLA4Ig: Tolerance induction of Th2 responses requires additional blockade of CD40-ligand. J. Immunol. 157:117-125, 1996.
64. Nickoloff BJ and Turka LA. Keratinocytes and the danger model. [letter]. Science 273:1379-1380, 1996.
65. Khoury SJ, Gallon L, Verburg, RR, Chandraker A, Peach R, Linsley PS, Turka LA, Hancock WW, and Sayegh MH. Ex-vivo treatment of antigen presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. J. Immunol 157:3700-3705, 1996.
66. Hancock WW, Sayegh MH, Zheng X-G, Peach R, Linsley PS, and Turka LA. Costimulatory Function and Expression of CD40-Ligand, CD80, and CD86 In Vascularized Murine Cardiac Allograft Rejection. Proc. Natl. Acad. Sci. (USA) 93:13967-13972, 1996.
67. Akalin E, Chandraker, A, Russell ME, Turka LA, Hancock WW, and Sayegh MH. CD28-B7 T cell costimulatory blockade by CTLA4Ig in the rat renal allograft model: inhibition of cell mediated and humoral immune responses in vivo. Transplantation. 62:1942-1945, 1996.
68. Bolling SF, Lin H, Turka LA. The time course of CTLAIg effect on cardiac allograft rejection. Journal of Surgical Research. 63:320-3, 1996.

69. Bolling SF, Lin H, Wei R-Q, and Turka LA. Preventing allograft rejection with CTLA4Ig: effect of DST route or timing. J. Heart. Lung Transpl. 15:928-935, 1996.
70. Akalin E, Chandraker A, Sayegh M, and Turka LA. The Role of the CD28:B7 Costimulatory Interaction in Alloimmune Responses. Kidney International 51:S8-S10, 1997.
71. Zheng XX, Sayegh MH, Zheng X-G, Linsley PS, Peach R, Borriello F, Strom TB, Sharpe AH, and Turka LA. The role of donor and recipient B7-1 (CD80) in allograft rejection. J Immunol. 159:1169-1173, 1997.
72. Zhang H, Yang Y, Horton JL, Samoilova EB, Judge TA, Turka LA, Wilson JM, and Chen Y. Amelioration of collagen-induced arthritis by Fas (CD95)-ligand gene transfer. J. Clin. Invest. 100:1951-1957, 1997.
73. Gallon L, Chandraker A, Peach R, Linsley PS, Turka LA, Sayegh MS, Khoury SJ. Differential effects of B7-1 blockade in the rat experimental autoimmune encephalomyelitis model. J Immunol 159:4212-4216, 1997.
74. Olthoff KM, Da Shen X, Gelman AE, Turka LA, and Shaked A. Adenovirus-mediated gene transfer of CTLA4Ig to liver allografts results in prolonged survival and local T-cell anergy. Transpl. Proc. 29:1030-1, 1997.
75. Eck SC, Chang D, Wells A, and Turka LA. Differential down-regulation of CD28 by B7-1 and B7-2 engagement. Transplantation 64:1497-1499, 1997.
76. Wells AD, Gudmundsdottir H, and Turka LA. Following the fate of individual T cells throughout activation and clonal expansion: signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. J. Clin. Invest. 100:3173-3183, 1997.
77. Tang A, Judge TA and Turka LA. Blockade of CD40/CD40L pathway induces tolerance in murine contact hypersensitivity. Eur. J. Immunol. 27:3143-3150, 1997.
78. Sayegh MH, Zheng X-G, Hancock WW, and Turka LA. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients. Transplantation 64:1646-1650, 1998.
79. Olthoff KM, Judge TA, Gelman AE, Da Shen X, Hancock WW, Turka LA, and Shaked A. Adenovirus-mediated gene transfer into cold-preserved liver allografts: survival pattern and tolerance following transduction with CTLA4Ig. Nature Medicine 4:194-200, 1998.
80. Schaub M, Stadlbauer THW, Chandraker A, Vella JP, Turka LA, and Sayegh MH. Comparative strategies to induce longterm graft acceptance in fully allogeneic renal versus cardiac allograft models by CD28-B7 T cell costimulatory blockade: role of thymus and spleen. J Am Soc Nephrol 9:891-898, 1998.
81. Jooss K, Turka LA, and Wilson JM. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Therapy 5:309-319, 1998.
82. Boxhorn HKE, Smith JG, Chang YJ, Guerry D, Lee WMF, Rodeck U, Turka LA, and Eck SL. Adenoviral transduction of melanoma cells with B7-1: anti-tumor immunity and immunosuppressive factors. Cancer Immunol and Immunotherapy 46:283-292, 1998.
83. Judge TA, Desai NM, Yang A, Rostami S, Alonso L, Zhang H, Chen Y, Markman J, DeMateo RP, Barker CF, Naji A, and Turka LA. Utility of adenoviral-mediated Fas ligand gene transfer to modulate islet allograft survival. Transplantation 66:426-434, 1998.
84. Zheng XG and Turka LA. Blocking T-cell costimulation to prevent transplant rejection. Transpl. Proc. 30:2146-49, 1998.
85. Hancock WW, Buelow R, Sayegh MH, and Turka LA. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat Med 4:1392-1396, 1998.
86. Judge TA, Wu Z, Zheng X-G, Sharpe AH, Sayegh MH, and Turka LA. The role of CD80, CD86 and CTLA-4 in alloimmune responses and the induction of long-term allograft survival. J. Immunol. 162:1947-51, 1999.

87. Gudmundsdottir H, Wells A, and Turka LA. Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferative capacity. J. Immunol. 162:5212-5223, 1999.
88. Wells AD, Gudmundsdottir H, and Turka LA. Single cell analysis of T cell responses in vitro and in vivo: role of costimulatory signals. Transpl. Proc. 31:814-815, 1999.
89. Li XC, Li Y, Dodge I, Wells AD, Zheng XX, Turka LA, and Strom TB. Induction of allograft tolerance in the absence of Fas mediated apoptosis. J Immunol 163:2500-25-7, 1999.
90. Eck SC, and Turka LA. Generation of protective immunity against an immunogenic carcinoma requires CD40/CD40L and B7/CD28 interactions but not CD4+ T cells. Cancer Immunol. and Immunother. 48:336-341, 1999.
91. Rosengard AM, Alonso LC, Korb LC, Baldwin WM, Sanfilippo F, Turka LA, and Ahearn JM. Functional characterization of soluble and membrane-bound forms of vaccinia virus complement control protein (VCP). Molecular Immunology 36:685-697, 1999.
92. Neylan JF, Sayegh MH, Coffman TM, Danovitch GM, Krensky AM, Strom TB, Turka LA, and Harmon WE. The allocation of cadaver kidneys for transplantation in the United States: consensus and controversy. J. Am. Soc. Nephrol. 10:2237-2243, 1999.
93. Chan SY, Li K, Piccotti JR, Louie MC, Judge TA, Turka LA, Eichwald EJ, and Bishop DK. Tissue specific consequences of the anti-adenoviral immune response: implications for cardiac transplants. Nature Medicine 5:1143-1149, 1999.
94. Li Y, Li XC, Wells AD, Zheng XX, Turka LA, and Strom TB. Blocking both signal 1 and signal 2 of T cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nature Medicine 5:1298-1302, 1999.
95. Wells AD, Li XC, Li Y, Walsh M, Zheng XX, Wu Z, Nuñez G, Tang A, Sayegh M, Hancock WW, Strom TB, and Turka LA. Requirement for T cell apoptosis in the induction of peripheral transplantation tolerance. Nature Medicine 5:1303-1307, 1999.
96. Issazadeh S, Abdallah K, Chitnis T, Chandraker A, Wells AD, Turka LA, Sayegh MH, and Khoury SJ. Role of passive T cell death in experimental autoimmune encephalomyelitis. J Clin Invest 105:1109-1116, 2000.
97. Schrum A, Wells A, and Turka LA. CD28 costimulation regulates TCR expression after cell activation. International Immunology 12:833-842, 2000.
98. Smiley ST, Csizmadia V, Gao W, Turka LA, and Hancock WW. Differential Effects of Cyclosporin A, Methylprednisolone, Mycophenolate and Rapamycin on CD154 Induction and Requirement for NFkB: Implications for Tolerance Induction. Transplantation (Rapid Communication) 70:415-419, 2000.
99. Wells AD, Walsh MC, Sankaran D, and Turka LA. T cell effector function and anergy avoidance are quantitatively linked to cell division. J Immunol 165:2432-2443, 2000.
100. Suchin E, Wells AD, and Turka LA. Quantifying the frequency of alloreactive cells in vivo: new answers to an old question. J Immunol 166:973-981, 2001.
101. Kim KS, Denton MD, Chandraker A, Knoflach A, Milord R, Waaga AM, Turka LA, Russell ME, Peach R, Sayegh MH. CD28-B7 mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am. J. Pathol., 158:977-986, 2001.
102. Wekerle T, Kurtz J, Sayegh MH, Ito H, Wells AD, Bensinger S, Shaffer J, Turka LA, and Sykes M. Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death. J Immunol 166:2311-2316, 2001.
103. Csizmadia V, Gao W, Hancock SA, Rottman JB, Wu Z, Turka LA, Siebenlist U, Hancock WW. Differential NF-kB and IkB gene expression during development of cardiac allograft rejection vs. CD154 mAb-induced tolerance. Transplantation 71:735-840, 2001.
104. Yamada A, Kishimoto K, Dong VM, Masayuki S, Anosova NG, Benichou G, Turka LA, Auchincloss H, and Sayegh MH. CD28 independent costimulation of T cells in alloimmune responses. J. Immunol. 167:140-146, 2001.

105. Eck S, and Turka LA. Adoptive transfer enables tumor rejection targeted against a self-antigen without the induction of autoimmunity. Cancer Res 61:3077-3083, 2001.
106. Li XC, Wells AD, Turka LA, and Strom TB. Death of alloreactive T cells sets the stage for immunoregulation to act. Transplant Proc 33:3014-3043, 2001.
107. Gudmundsdottir H and Turka LA. A closer look at homeostatic proliferation of CD4+ T cells: costimulatory requirements and role in memory formation. J Immunol 167:3699-3707, 2001.
108. Wells AD, Walsh MC, Bluestone JA, and Turka LA. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J Clin Invest 108:895-903, 2001.
109. Kreisel D, Krupnick AS, Gelman AE, Engles FH, Popma SH, Krasinskas AM, Balsara KR, Szeto WY, Turka LA, and Rosengard, BR. Non-hematopoietic allograft cells directly activate CD8+ T cells and trigger acute rejection: an alternative mechanism of allorecognition. Nature Medicine 8:233-239, 2002.
110. Makino Y, Cook DN, Smithies O, Hwang OY, Neilson EG, Turka LA, Sato H, Wells AD, and Danoff TM. Impaired T cell function in RANTES-deficient mice. Clin. Immunol. 3:302-302, 2002.
111. Kreisel D, Sankaran D, Wells AD, and Turka LA. Interleukin-2 mediated survival and proliferative signals are uncoupled in T lymphocytes that fail to divide after activation. Am J Transplant 2:120-128, 2002.
112. Seo S-J, Fields ML, Reed AJ, Buckler J, Potts KM, Noelle RJ, Turka LA, Caton AJ, Finkelman FD, and Erikson J. The availability of T cell help dictates the fate of anti-dsDNA B cells at two distinct checkpoints. Immunity 16:535-546, 2002.
113. Kishimoto K, Sandner S, Imitola J, Sho M, Li Y, Langmuir PB, Rothstein DM, Strom TB*, Turka LA*, and Sayegh MH*. Differing roles of Th1 cytokines and T cell death in transplant tolerance as a function of the alloreactive T cell clone size. J Clin Invest 109:1471-1479, 2002. * - Co-senior authors.
114. Krupnick AS, Kreisel D, Popma SH, Balsara KR, Szeto WY, Krasinskas AM, Riha M, Wells AD, Turka LA, and Rosengard BR. Mechanism of T cell-mediated endothelial apoptosis. Transplantation. 74:871-876, 2002.
115. Schrum A and Turka LA. The proliferative capacity of individual naive CD4+ T cells is amplified by prolonged T cell antigen receptor (TCR) triggering. J Exp Med 196:793-803, 2002.
116. Kreisel D, Krupnick AS, Balsara KR, Riha M, Szeto WY, Gelman AE, Popma SH, Krasinskas AM, Turka LA, and Rosengard BR. Mouse vascular endothelium activates CD8+ T lymphocytes in a B7-dependent fashion. J Immunol 169:6154-6161, 2002.
117. Liu Q-H, Fleischmann BK, Hondowicz B, Maier CC, Turka LA, Yui K, Kotlikoff MI, Wells AD and Freedman BD. Distinct changes in Kv channel expression are associated with CD4+ T cell proliferation and anergy. J Exp Med 196:897-909, 2002.
118. Sayegh MH, Hancock WW, Wu Z, Langmuir PB, Mata M, Sandner S, Kishimoto K, Sho M, Palmer E, Mitchell RN, and Turka LA. Allograft rejection in a new allospecific $CD4^+$ TCR transgenic mouse. Am J Transpl 3:381-389, 2003.
119. Wells AS, Liu Q-H, Hondowicz B, Zhang J, Turka LA and Freedman B. Regulation of T cell activation and tolerance by PLCg 1-dependent integrin avidity modulation. J Immunol 170:4127-4133, 2003.
120. Kurts J, Lie A, Griffith M, Eysaman S, Shaffer J, Anosova N, Turka L, Benichou G, and Sykes M. Lack of role for CsA-sensitive or Fas-pathways in the tolerization of CD4 T cells via BMT and anti-CD40L. Am J Transpl 3:804-816, 2003.
121. Chung JB, Wells AD, Adler S, Turka LA, and Monroe JG. Antigen presentation by immature B cell leads to costimulation-dependent modulation of T cell responses and B cell negative selection. J Immunol 171:1758-1767, 2003.
122. Sandner S, Salama AD, Housner SL, Palmer E, Turka LA, and Sayegh MH. A new TCR transgenic model for tracking allospecific CD4+ T cell activation and tolerance in vivo. Am J Transpl 3:1241-1250, 2003.

123. Kobayashi T, Walsh PT, Walsh MC, Speirs KM, Chiffoleau E, King CG, Hunter CA, Scott P, Turka LA, and Choi Y. TRAF6 is a critical factor for dendritic cell maturation and development. Immunity 19:353-363, 2003.
124. Adler SH, Chiffoleau E, Xu L, Wells AD, Wolfe MS, Turka LA*, and Pear WS*. Notch signaling augments T cell responsiveness by enhancing CD25 expression. J Immunol 171:2896-2903, 2003. * - Co-senior authors.
125. Burchill MA, Goetz CA, Prlic M, O'Neil JJ, Harmon IR, Bensinger SJ, Turka LA, Brennan P, Jameson SC, and Farrar MA. Distinct effects of STAT5 activation on $CD4^+$ and $CD8^+$ T cell homeostasis: development of $CD4^+CD25^+$ regulatory T cells versus $CD8^+$ memory T cells. J Immunol 171: 5853-5864, 2003.
126. Chiffoleau E, Kobayashi T, Walsh MC, King CG, Walsh PT, Hancock WW, Choi Y and Turka LA. TRAF6 deficiency during hematopoiesis induces Th2 polarized inflammatory disease. J Immunol 171: 5751-5759, 2003.
127. Guillonneau C, Louvet C, Renaudin K, Heslan J-M, Heslan M, Tesson L, Vignes C, Guillot C, Choi Y, Turka LA, Cuturi M-C, Anegon I, and Josien R. The role of TNF-related activation-induced cytokine-receptor activation NF-kB interaction in acute allograft rejection and CD40L-independent chronic allograft rejection. J Immunol 172:1619-1629, 2004.
128. Mata M*, Chiffoleau E*, Adler SA, Gray T, Hancock W, and Turka LA. Bcl-XL expression in stem cells facilitates engraftment and reduces the need for host conditioning during bone marrow transplantation. Am J Transpl 4:58-64, 2004. * - Co-first authors.
129. Wu Z, Bensinger SJ, Zhang J, Chen C, Yuan X, Huang X, Markmann J, Kassaee A, Rosengard BR, Hancock WW, Sayegh MS and Turka LA. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 10:87-92, 2004.
130. Bensinger SJ, Walsh P, Zhang J, Carroll M, Parsons R, Rathmell JC, Thompson CB, Burchill MA, Farrar MA, and Turka LA. Distinct IL-2R signaling pattern in CD4+CD25+ regulatory T cells. J Immunol 172:5287-5296, 2004.
131. Gelman AE, Zhang J, and Turka LA. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol 172:6065-6073, 2004.
132. Krasinskas AM, Kreisel K, Szeto WY, Wu Z, Rosengard AM, Popma SH, Moore, JS, Turka LA, and Rosengard BR. Endothelium does not contribute to CD4+ direct allorecognition in vivo. J Immunol 173:3027-3034, 2004.
133. Biju MP,* Neumann AK*, Bensinger SJ, Johnson RS, Turka LA, and Haase VH. *VHL* tumor suppressor gene deletion induces HIF-1 mediated cell death in thymocytes. Mol Cell Biol 24:9038-9047, 2004. * - Co-first authors.
134. Sandner SE, Clarkson MR, Salama AD, Sanchez-Fueyo A, Yagita H, Turka LA, and Sayegh MH. Mechanisms of tolerance induced by donor-specific transfusion and ICOS-B7h blockade in a model of CD4+ T cell mediated allograft rejection. Am J Transpl 5:31-39, 2005.
135. Schrum AG, Palmer E, and Turka, LA. Distinct temporal programming of naïve CD4+ T cells for cell division versus TCR-dependent death susceptibility by antigen presenting-macrophages. Eur J Imm 35:449-459, 2005.
136. Sandner SE, Clarkson MR, Salama AD, Sanchez-Fueyo A, Domenig C, Habicht A, Najafian N, Yagita H, Azuma M, Turka LA and Sayegh MH. Functions of the programmed death-1 (PD-1) pathway in regulation of alloimmune responses in vivo. J Immunol 174:3408-3415, 2005.
137. Schenk S, Kish DD, He C, El-Sawy T, Chiffoleau E, Chen C, Wu Z, Sandner S, Gorbachev A, Fukamachi K, Heeger PS, Sayegh MH, Turka LA*, and Fairchild RL*. Alloreactive T cell responses and acute rejection of single class II MHC-disparate heart allografts are under strict regulation by CD4+CD25+ T cells. J Immunol 174:3741-3748, 2005. * - Co-senior authors.
138. Krupnick A, Gelman AE, Barchet W, Richardson S, Kreisel FH, Turka LA, Colonna M, Paterson GA, and Kreisel D. Cutting Edge: Murine vascular endothelium activates and

induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells. J Immunol 175:6265-6270, 2005.

139. Neumann AK, Yang J, Biju MP, Joseph SK, Johnson RS, Haase VH, Freedman BD, and Turka LA. Hypoxia Inducible Factor-1a Regulates T Cell Receptor Signal Transduction. Proc Natl Acad Sci (USA) 102:17071-17076, 2005.
140. Sanchez-Fueyo A, Sandner S, Habitch A, Marieat C, Kenny J, Degauque N, Zheng XX, Strom TB, Turka LA*, and Sayegh MH*. Specificity of CD4+CD25+ regulatory T cell function in alloimmunity. J Immunol 176:237-247, 2006. *-co-senior authors.
141. Vu MD, Clarkson MR, Yagita H, Turka LA, Sayegh MH, and Li XC. Critical but conditional role of OX40 in memory T cell mediated rejection. J Immunol 176:1394-1401, 2006.
142. Walsh PT, Benoit BM, Wysocka M, Dalton NM, Turka LA, and Rook AH. Association between cutaneous T cell lymphoma and regulatory T cells: Induction of a regulatory T cell phenotype through HTLV-1 infection. J Invest Derm 126:690-692, 2006.
143. Neujahr DC, Chen C, Huang X, Markmann FJ, Cobbold S, Waldmann H, Sayegh MH, Hancock WW, and Turka LA. Selective advantage of memory T cells in the setting of induced lymphophenia: impact on allograft survival. J Immunol 176:4632-9, 2006.
144. Benigni A, Tomasoni S, Turka LA, Longaretti L, ZentilinL, Mister M, Pezzotta A, Azzollini N, Noris M, Conti S, Abbate M, Giacca M, and Remuzzi G. Adeno-associated virus-mediated CTLA4Ig gene transfer protects MHC-mismatched renal allografts from chronic rejection. J Am Soc Nephrol 17:1665-72, 2006.
145. Hickman SP, Yang J, Thomas RM, Wells AD, and Turka LA. Defective activation of PKC and Ras-Erk pathways limits IL-2 production and proliferation by CD4+CD25+ regulatory T cells. J Immunol 177:2195-2207, 2006.
146. Taylor DK, Walsh PT, LaRosa DF, Zhang J, Burchill MA, Farrar MA, and Turka LA. Constitutive activation of STAT5 supersedes the requirement for cytokine and TCR engagement of $CD4^+$ T cells in steady state homeostasis. J Immunol 177:2216-2223, 2006.
147. King CG, Kobayashi T, Cejas PJ, Kim T, Yoon K, Kim GK, Chiffoleau E, Hickman SP, Walsh PT, Turka LA, and Choi Y. TRAF6 is a T cell intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Med 9:1088-1092, 2006.
148. Walsh PT, Buckler JL, Zhang J, Gelman AE, Dalton NM, Taylor DK, Bensinger SJ, Hancock WW, and Turka LA. PTEN regulates the IL-2 receptor responsiveness of CD4+CD25+ regulatory T cells. J Clin Invest 116:2521-2531, 2006.
149. Buckler JL, Walsh PT, Porrett PM, Choi Y, and Turka LA. Cutting Edge: T cell requirement for CD28 costimulation is due to negative regulation of TCR signals by PTEN. J Immunol 177:4262-4266, 2006.
150. Gelman AE, LaRosa DF, Zhang J, Walsh PT, Choi Y, Sunyer O, and Turka LA. The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4(+) T cells and enables CpG oligodeoxynucleotide-mediated costimulation. Immunity 25:783-793, 2006.
151. LaRosa DF, Gelman AE, Rahman AH, Zhang J, Turka LA, and Walsh PT. CpG DNA inhibits CD4+CD25+ Treg suppression through direct MyD88-dependent costimulation of effector CD4+ T cells. Immunol Letters 108:183-188, 2007.
152. Schrum AG, Gil D, Dopfer EP, Wiest DL, Turka LA, Schamel WW, and Palmer E. Sci STKE 2007: pl2, 2007.
153. Dzierszinski F, Pepper M, Stumhofer JS, LaRosa DF, Wilson EH, Turka LA, Halonen SK, Hunter CA, and Roos DS. Presentation of Toxoplasma gondii antigens via the endogenous major histocompatibility complex class I pathway in nonprofessional and professional antigen-presenting cells. Infect Immun 75:5200-09, 2007.
154. Tao R, de Zoeten EF, Özkaynak E, Chen C, Wang L, Porrett PM, Li B, Turka LA, Olson EN, Greene MI, Wells AD, and Hancock WW. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 13:1299-1307, 2007.

155. Stumhofer JS, Silver JS, Laurence A, Porrett PM, Harris TH, Turka LA, Ernst M, Saris CJM, O'Shea JJ, and Hunter CA. Interleukins 27 and 6 induce T cell production of interleukin 10 mediated by transcription factor STAT3. Nat Imm 12:1363-71, 2007.
156. Yang J, Brook MO, Carvalho-Gaspar M, Zhang J, Ramon HE, Sayegh MH, Wood KJ, Turka LA*, and Jones ND. Allograft rejection by memory T cells is resistant to regulation. Proc Natl Acad Sci (USA) 104:19954-59, 2007 (Track II – direct – submission). *corresponding author
157. King CG, Buckler JL, Kobayahsi T, Hannah JR, Bassett G, Kim T, Pearce EL, Kim GG, Turka LA and Choi Y. Cutting Edge: Requirement for TRAF6 in the induction of T cell anergy. J Immunol 180:34-38, 2008.
158. Ueno T, Habicht A, Clarkson MR, Albin MJ, Yamaura K, Boenisch O, Popoola J, Wang Y, Yagita H, Akiba H, Ansari MJ, Yang J, Turka LA, Rothstein DM, Padera RF, Najafian N, and Sayegh MH. The emerging role of T cell immunoglobulin mucin 1 (Tim-1) in alloimmune responses in vivo. J Clin Invest 118; 742-751, 2008.
159. Bloom DD, Chang Z, Fechner JH, Dar W, Polster SP Pascual J, Turka LA, and Knechtle SJ. CD4+CD25+FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transpl 8:793-202, 2008.
160. LaRosa DF, Stumhofer JS, Gelman AE, Rahman AH, Taylor DK, Hunter CA, and Turka LA. T cell expression of myeloid differentiation protein 88 is required for resistance to *Toxoplasma gondii*. Proc Natl Acad Sci (USA) 105:3855-60, 2008 (Track II – direct submission).
161. Porrett PM, Yuan X, LaRosa DF, Walsh PT, Yang J, Gao W, Li P, Zhang J, Ansari JM, Hancock WW, Sayegh MH, Koulmanda M, Strom TB, and Turka LA. Mechanisms underlying blockade of allograft acceptance by TLR ligands. J Immunol 181:1692-1699, 2008.
162. Rahman AH, Cui W, LaRosa DF, Taylor DK, Zhang J, Goldstein DR, Wherry EJ, Kaech SM*, and Turka LA*. MyD88 plays a critical T cell-intrinsic role in supporting CD8 T cell expansion during acute LCMV infection. J Immunol 181:3804-3810, 2008. *co-senior authors.
163. Allenspach AJ, Lemos MP, Porrett PM, Turka LA, and Laufer TM. Migratory and lymphoid-resident dendritic cells cooperate to efficiently prime naïve CD4 T cells. Immunity 29:795-806, 2008.
164. Yuan X, Ansari MJ, D'Addio F, Paez-Cortez J, Schmitt-Knosalla I, Donnarumma M, Boenisch O, Popoola J, Clarkson MR, Yagita H, Hisaya A, Freeman GJ, Iacomini J, Turka LA, Glimcher LH, Sayegh MH. Targeting TIM-1: to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proc Natl Acad Sci 106:10734-9, 2009.
165. Yang J, Riella LV, Boenisch O, Popoola J, Robles S, Watanabe T, Vanguri V, Yuan X, Guleria I, Turka LA, Sayegh MH, Chandraker A. Paradoxical Functions of B7: CD28 Costimulation in a MHC Class II-Mismatched Cardiac Transplant Model. Am J Transpl 9:2837-44, 2009.
166. Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, Burlingham WJ, Marks WH, Sanz I, Lechler RI, Hernandez-Fuentes MP, Turka LA*, Seyfert-Margolis VL*, and the ITN ST507 Study Group. Tolerant renal transplant recipients: evidence for a B-cell signature associated with tolerance in humans. J Clin Invest 120:1836-47, 2010.
167. Liu X, Karnell JL, Yin B, Zhang R, Zhang J, Li P, Choi Y, Maltzman JS, Pear WS, Bassing CH, and Turka LA. Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice. J Clin Invest 120:2497, 2010.
168. Cejas PJ, Walsh, MC, Pearce EL, Han D, Harms GM, Artis D, Turka LA, and Choi Y. TRAF6 inhibits Th17 differentiation and TGF-beta-mediated suppression of IL-2. Blood 115:4750, 2010.

169. D'Addio F, Yuan X, Habicht A, Williams J, Ruzek M, Iacomini J, Turka LA, Sayegh MH, Najafian H, and Ansari MJ. A novel clinically relevant approach to tip the balance towards regualtion in a stringent transplant model. Transplantation (in press).
170. Ramón HE, Cejas PJ, LaRosa D, Rahman A, Harris JE, Zhang J, Hunter C, Choi Y, and Turka LA. EGR-2 is not required for in vivo CD4 T cell mediated immune responses. PloSONE (in press).

Reviews, Chapters and Editorials:

1. Turka LA. Urinary Tract Obstruction. In: Rose BD, Pathophysiology of Renal Disease. 2nd ed. New York: McGraw Hill, 1987:447-467.
2. Rose BD, and Turka LA. Diuretics. In: Kaplan NM, Brenner BM, and Laragh JH, eds. The Kidney in Hypertension. New York: Raven Press, 1987:179-197.
3. Turka LA, and Rose BD. Clinical Aspects of Urinary Tract Obstruction. In: Brenner BM, and Lazarus JM, eds. Acute Renal Failure. 2nd Ed. New York: Churchill Livingstone, 1988:581.
4. Turka LA and Thompson CB. Structure-function relationship of immunosuppressive drugs: a cautionary tale. (Editorial) Hepatology 14:570-572, 1991.
5. Dayton JS, Turka LA, Thompson CB, and Mitchell BS. Guanine Ribonucleotide Depletion Inhibits T Cell Activation. In: Harkness RA et al, eds. Purine and Pyrimidine Metabolism in Man VII, Part B. New York: Plenum Press, 1991:293-296.
6. Thompson CB, Jackson KM, Turka LA, Mitchell, BS, and June CH. Development of an in vitro model system to study the physiologic effects of immunosuppresants. In: Vol. 7 - Alternative Methods in Toxicology Book Series, 7th International CAAT Symposium, In Vitro Toxiology - Mechanisms and New Technology, Mary Ann Liebert Inc., New York 1991:55
7. Turka LA. Transplantation Immunology. In: Kelley, WN, ed. Textbook of Internal Medicine. 2nd Ed. Philadelphia: J.B. Lippincott, 1992:698.
8. Turka LA. T cell selection. In: Humes, HD, ed. The Kidney. National Kidney Foundation, New York, 1993, 3:1-8.
9. Turka LA and Thompson CB. Cytokines and liver transplantation. Reg. Peptide Letter 1993, 4:71-75.
10. Nickoloff BJ and Turka LA. Keratinocytes - key immunocytes of the integument. (Review Article) Am. J. Path. 143:325-331, 1993.
11. Dayton JS and Turka LA. Mizoribine. In: Kupiec-Weglinski, JW., ed., New Immunosuppressive Modalities and Anti-Rejection Approaches in Organ Transplantation. R.G. Landes Biomedical Publishers, Austin, 1994; 31-42.
12. Gratiot-Deans J and Turka LA. New biological immunosuppressive agents. In: Koch D, and Halloran P, eds. Current Opinion in Nephrology and Hypertension, 3:596-601, 1994.
13. Judge TA and Turka LA. Costimulatory pathway blockade. In: Salomon DR, ed., Recent Developments in Transplantation Medicine II - Adhesion Molecules and Monoclonal Antibodies. Physicians and Scientists Publishing Co., Inc., Glenview, IL, 1995, 79-96.
14. Judge TA, Tang A, and Turka LA. Immunosuppression through blockade of CD28:B7-mediated costimulatory signals. Immunologic Res. 15:38-49, 1996.
15. Turka LA and Sayegh MH. T cell tolerance. In: Tilney NL, Strom TB, and Paul LC eds., Transplantation Biology: Cellular and Molecular Aspects. 1st Ed.; Raven Press 1996, 503-514.
16. Turka LA. The role of accessory molecules for T cell activation and allograft rejection. J. Nephrology 9:179-185, 1996.
17. Turka LA. Normal immune response. In: Neilson, EG and Couser WG eds., Immunologic Renal Diseases. 1st Ed.; Raven Press 1997, 65-94.
18. Aradhye S and Turka LA. Will tolerance become a clinical reality? Am. J. Med. Sci. 313:310-314, 1997.

19. Aradhye S and Turka LA. Immunosuppressive therapy in immunologic renal disease and transplantation. In: Brady HR and Wilcox CS eds., Therapy in nephrology and hypertension: a companion to Brenner and Rector's The Kidney. 1st Ed.: Saunders 1998, 89-95.
20. Wells AD and Turka LA. Individual T cells hold unexpected clues to the nature of anergy and memory. Immunologic Res. 17:261-268, 1998.
21. Turka LA. What's new in transplant immunology: problems and prospects. Ann. Int. Med. 128:946-948, 1998.
22. Zheng X-G and Turka LA. Chronic rejection – is tolerance the answer? Graft 1:45-6, 1998.
23. Turka LA. Ed. Will tolerance become a clinical reality? Graft 1:111-116, 1998.
24. Turka LA. Normal immune responses. In: Norman, DJ and Suki WN eds., Primer on Transplantation. 1st Ed.; American Society of Transplant Physicians, 1998, 7-20.
25. Sayegh MH and Turka LA. The role of T cell co-stimulatory activation pathways in transplant rejection. N. Engl. J. Med. 338:1813-1821, 1998.
26. Vella JP, Sayegh MH, and Turka, LA. Developments in the clinical science of transplantation during the 20th Century. Pediatric Transplantation 2:257-262, 1998.
27. Khoury S, Sayegh MH, and Turka, LA. Blocking costimulatory signals to induce transplantation tolerance and prevent autoimmune disease. Intern. Rev. Immunol. 18:185-199, 1999.
28. Gudmundsdottir H, and Turka LA. T cell costimulatory blockade: new therapies for transplant rejection. J. Am. Soc. Nephrol. 10:1356-1365, 1999.
29. Gudmundsdottir H, and Turka LA. Transplantation tolerance: mechanisms and strategies. Seminars in Nephrology 20:209-217, 2000.
30. Bloom RD, and Turka LA. Costimulation Blockade. In: Sayegh MH and Remuzzi G, Eds., Current and future immunosuppression strategies following transplantation , 1st Ed.;Kluwer Academic Publishers, Dordrecht, The Netherlands, 2001.
31. Li XC, Wells AD, Strom TB, and Turka LA. The role of apoptosis in transplantation tolerance. Current Opinion in Immunology 12:522-527, 2000.
32. Rosengard BR, and Turka LA. Looking good in someone else's genes (Editorial). J Clin Invest 107:33-34, 2001.
33. Wells AD, Li XC, Strom TB, and Turka LA. Apoptosis in transplantation. Phil. Trans. Royal. Soc. 356:1-7, 2001.
34. Wells AD, and Turka LA. The role of apoptosis in the induction and maintenance of transplantation tolerance. Current Opinion in Organ Transplantation 6:1-6, 2001.
35. Li XC, Strom TB*, Turka LA*, and Wells AD. T cell death and transplantation tolerance. Immunity 14:407-416. 2001. * - senior authors.
36. Turka LA. Normal immune responses. In: Norman DJ and Turka LA eds., Primer on Transplantation. 2nd Ed.; American Society of Transplant Physicians, 2001, p. 3-15.
37. Adler SH, Bensinger SJ, Turka LA. Stemming the tide of rejection. Nature Medicine 8:107-8, 2002.
38. Adler SH and Turka LA. Immunotherapy as a means to induce transplantation tolerance. Current Opinion in Immunology 14:660-665, 2002.
39. Lechler RI, Sykes M, Thomson AW, and Turka LA. Designer meetings. Nat Immunol 3:791, 2002.
40. Doyle AM, Turka LA, and Bloom RD. Immunosuppressive therapy in immunologic renal disease and transplantation. In: Brady HR and Wilcox CS eds., Therapy in nephrology and hypertension: a companion to Brenner and Rector's The Kidney. 2nd Ed.: Saunders 2003 99-108.
41. Lechler RI, Garden OA, and Turka LA. The complementary roles of deletion and regulation in transplantation tolerance. Nat Reviews Imm 3:147-158, 2003.
42. Chiffoleau E, Walsh P, and Turka LA. Apoptosis and Transplantation Tolerance. Imm Rev 193:124-135, 2003.

43. Schrum AG, Turka LA, and Palmer E. Surface T-cell antigen receptor expression and availability for long-term antigenic signaling. Imm Rev 196:7-24, 2003.
44. Gelman AE and Turka LA. Autoimmunity heats up. Nat Med 9:1465-66, 2003.
45. Walsh PT, Strom TB and Turka LA. Routes to transplant tolerance versus rejection: the role of cytokines. Immunity 20:121-131, 2004.
46. Monroe JG and Turka LA. Regulation of activation of B and T lymphocytes. In: Hoffman et al eds., Hematology: Basic principles and practice. 4th Ed.: Elsevier, 2004.
47. Taylor DK, Neujahr D, and Turka LA. Heterologous immunity and homeostatic proliferation as barriers to tolerance. Curr Opin Immunol 16:558-564, 2004.
48. Neujahr D and Turka LA. Lymphocyte depletion as a barrier to immunological tolerance. In: Ronco C, Chiaramonte S, and Remuzzi G eds., Kidney transplantation: strategies to prevent organ rejection. Contrib Nephrol. Basel, Karger 146:65-72, 2005.
49. Walsh PT, Taylor DK, and Turka LA. Regulatory T cells and transplantation tolerance. J Clin Invest 114:1398-1403, 2004.
50. Doyle AM, Lechler RI, and Turka LA. Organ transplantation: Halfway through the first century. J Am Soc Neprhol 15:2965-2971, 2004.
51. Hickman SP and Turka LA. Homeostatic T cell proliferation as a barrier to tolerance. Phil. Trans. Royal. Soc. 360:1713-1721, 2005.
52. Lechler RI, Sykes M, Thomson AW, and Turka LA. Organ transplantation – how much of the promise has been realized. Nat Med 11:605-613, 2005.
53. Bluestone JA, St. Clair EW, and Turka LA. CTLA4Ig: Bridging the basic immunology with clinical application. Immunity 24:233-238. 2006.
54. St. Clair EW, Turka LA, Saxon A, Matthews JB, Sayegh MH, Eisenbarth G, and Bluestone J. New reagents on the horizon for immune tolerance. Ann Rev Med 58:329-46, 2007.
55. Maltzman J, and Turka LA. Conditional gene expression: a new tool for the transplantologist. Am J Tranpl 7:733-740, 2007.
56. LaRosa DF, Rahman AH, and Turka LA. The innate immune system in allograft rejection and tolerance. J Immunol 178:7503-7509, 2007.
57. Turka LA. Lost in a dark wood. J Clin Invest 117:1734-5, 2007.
58. Neill U and Turka LA. Navingating through the gray (and CMYK) areas of figure manipulation: rules at the *JCI*. J Clin Invest 117:2736, 2007.
59. Turka LA. A method to our madness. J Clin Invest 117:3144, 2007.
60. Turka LA and Walsh PT. IL-2 signaling and CD4+CD25+foxp3+ regulatory T cells. Frontiers in Bioscience 13:1440-46, 2008.
61. Turka LA. Animal House. J Clin Invest 118: 822, 2008.
62. Sawtizki B, Reinke P, Volk H-D, Wood K, and Turka LA. Autoimmunity and transplantation: a meeting at the crossroads in Berlin. Nat Imm 9:447-449, 2008.
63. Seyfert-Margolis V, and Turka LA. Marking a path to transplant tolerance. J Clin Invest 118:2684, 2008.
64. Buckler JL, Liu X, and Turka LA. Regulation of T cell responses by PTEN. Imm Rev 224:239-248, 2008.
65. Rahman AH, Taylor DK, and Turka LA. The contribution of direct TLR signaling to T cell responses. Imm Rev 45:25-36, 2009.
66. Turka LA. Senator, what is your policy on . . . “Other”? J Clin Invest 118:2988, 2008.
67. Neill US and Turka LA. Bothered and bewildered, but not bewitched. J Clin Invest 118:3516, 2008.
68. Turka LA. After further review. J Clin Invest 119:1057, 2009.
69. Lechler RI and Turka LA. Towards the identification of biomarkers of transplantation tolerance. Nat Rev Immunol 9:521-526, 2009.
70. Bluestone JA, Krensky AM, Turka LA, Rotrosen D, and Matthews JB. Ten years of the Immune Tolerance Network: An intergrated clinical research organization. Sci Tran Med 2:19, 2010.
71. Turka LA and Caplan AL. The right to health care. J Clin Invest 120:934, 2010.

72. Turka LA, Wood K, and Bluestone JA. Bringing transplant tolerance into the clinic: lessons from the ITN and RISET consortia. Curr Op Organ Transp 15:441, 2010.
73. Li XC and Turka LA. An update on regulatory T cells in transplant tolerance and rejection. Nature Reviews Nephrology (in press).
74. Bluestone JA, Auchincloss H, Nepom GT, Rotrosen D, St. Clair EW, and Turka LT. The Immune Tolerance Network at 10 years – tolerance research at the bedside. Nat Rev Immunol (in press).

Books:

1. Turka LA, Section Editor, Immunology/Immunogenetics, in Norman, DJ and Suki WN eds., Primer on Transplantation. 1st Ed.; American Society of Transplant Physicians, 1998, 5-80.
2. Turka LA, Section Editor, Pharmacology/Immunosuppression, in Norman, DJ and Suki WN eds., Primer on Transplantation. 1st Ed.; American Society of Transplant Physicians, 1998, 5-80.83-138.
3. Editor, Norman, DJ and Turka LA eds., Primer on Transplantation. 2nd Ed.; American Society of Transplant Physicians, 2001.

Online:

Turka, L. (2007), "Antibody Depletion Therapy in Transplantation: Implications for Tolerance", in Waldmann, H. (ed.), Monoclonal Antibodies as Therapeutic Agents: Fundamentals, Therapeutic Applications and Latest Advances, The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London (online at http://www.hstalks.com/?t=BL0471248-Turka)

Patents:

Patent	Title	Name	Issue Date
US Provisional Patent 60/685,837	"Manipulation of PTEN in T cells as a strategy to modulate immune responses".	Turka, LA	Pending
US Provisional Patent 60/763,419	"Manipulation of PTEN in T cells as a strategy to modulate immune responses".	Turka, LA	Pending
US Provisional Patent 60/691,606	"Stimulation of Toll Like Receptors on T cells",	Turka, LA	Pending